Antares Pharma (ATRS) 10-K12 Mar 152014 FY Annual reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
Document and Entity Information (USD $)	Dec. 31, 2014	Mar. 07, 2015	Jun. 30, 2014
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Trading Symbol	ATRS
Entity Registrant Name	ANTARES PHARMA, INC.
Entity Central Index Key	1016169
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		131,743,365
Entity Public Float			$313,638,000

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current Assets:
Cash and cash equivalents	$34,028,889	$39,067,236
Short term investments	6,002,438	24,014,305
Accounts receivable	3,510,051	1,034,492
Inventories	5,859,924	6,461,051
Deferred costs	1,913,921	375,773
Prepaid expenses and other current assets	2,322,464	1,706,678
Total current assets	53,637,687	72,659,535
Equipment, molds, furniture and fixtures, net	10,828,741	6,952,251
Patent rights, net	2,885,024	1,345,177
Goodwill	1,095,355	1,095,355
Long term investments		6,008,169
Other assets	325,955	871,444
Total Assets	68,772,762	88,931,931
Current Liabilities:
Accounts payable	10,071,504	6,378,712
Accrued expenses and other liabilities	5,635,559	5,453,075
Deferred revenue	8,520,517	4,531,220
Total current liabilities	24,227,580	16,363,007
Deferred revenue - long term	3,349,026	1,855,196
Total liabilities	27,576,606	18,218,203
Stockholders' Equity:
Preferred Stock: $0.01 par; authorized 3,000,000 shares, none outstanding
Common Stock: $0.01 par; authorized 200,000,000 shares; 131,743,365 and 128,740,604 issued and outstanding at December 31, 2014 and 2013, respectively	1,317,433	1,287,406
Additional paid-in capital	249,032,066	243,375,465
Accumulated deficit	-208,447,656	-173,295,941
Accumulated other comprehensive loss	-705,687	-653,202
Total Stockholders' Equity	41,196,156	70,713,728
Total Liabilities and Stockholders' Equity	$68,772,762	$88,931,931

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]
Preferred Stock, par value	$0.01	$0.01
Preferred Stock, shares authorized	3,000,000	3,000,000
Preferred Stock, shares outstanding	0	0
Common Stock, par value	$0.01	$0.01
Common Stock, shares authorized	200,000,000	200,000,000
Common Stock, shares issued	131,743,365	128,740,604
Common Stock, shares outstanding	131,743,365	128,740,604

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
Consolidated Statements of Operations (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenue:
Product sales	$13,195,577	$10,957,932	$9,137,573
Development revenue	7,246,080	4,139,672	7,422,412
Licensing revenue	3,708,938	849,185	2,141,309
Royalties	2,351,070	4,671,711	3,874,284
Total revenue	26,501,665	20,618,500	22,575,578
Cost of revenue:
Cost of product sales	9,359,457	6,990,186	6,116,726
Cost of development revenue	1,877,238	2,207,044	3,403,746
Total cost of revenue	11,236,695	9,197,230	9,520,472
Gross profit	15,264,970	11,421,270	13,055,106
Operating expenses:
Research and development	18,638,016	15,263,371	14,921,552
Selling, general and administrative	31,740,249	17,008,216	9,585,053
Total operating expenses	50,378,265	32,271,587	24,506,605
Operating loss	-35,113,295	-20,850,317	-11,451,499
Other income (expense):
Interest income	76,661	111,577	63,195
Foreign exchange gain (loss)	156	-8,853	14,414
Other, net	-90,237	-59,183	-53,560
Total other income (expense)	-13,420	43,541	24,049
Net loss before income taxes	-35,126,715	-20,806,776	-11,427,450
Income tax provision (benefit)	25,000	-300,000
Net loss	($35,151,715)	($20,506,776)	($11,427,450)
Basic and diluted net loss per common share	($0.27)	($0.16)	($0.10)
Basic and diluted weighted average common shares outstanding	130,549,701	126,897,247	110,185,077

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (USD $)	12 Months Ended
Consolidated Statements of Comprehensive Loss (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Statement of Comprehensive Income [Abstract]
Net loss	($35,151,715)	($20,506,776)	($11,427,450)
Foreign currency translation adjustment	-52,485	12,143	-70,020
Comprehensive loss	($35,204,200)	($20,494,633)	($11,497,470)

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Balance at Dec. 31, 2011	$31,143,845	$1,035,456	$172,065,429	($141,361,715)	($595,325)
Balance, shares at Dec. 31, 2011		103,545,637
Issuance of common stock	53,328,188	142,599	53,185,589
Issuance of common stock, shares		14,259,868
Exercise of warrants and options	11,579,413	80,217	11,499,196
Exercise of warrants and options, shares		8,021,672
Stock-based compensation	1,996,616	1,218	1,995,398
Stock-based compensation, shares		121,847
Net loss	-11,427,450			-11,427,450
Other comprehensive loss	-70,020				-70,020
Balance at Dec. 31, 2012	86,550,592	1,259,490	238,745,612	-152,789,165	-665,345
Balance, shares at Dec. 31, 2012		125,949,024
Exercise of warrants and options	2,326,838	24,523	2,302,315
Exercise of warrants and options, shares		2,452,254
Stock-based compensation	2,330,931	3,393	2,327,538
Stock-based compensation, shares		339,326
Net loss	-20,506,776			-20,506,776
Other comprehensive loss	12,143				12,143
Balance at Dec. 31, 2013	70,713,728	1,287,406	243,375,465	-173,295,941	-653,202
Balance, shares at Dec. 31, 2013		128,740,604
Exercise of warrants and options	3,105,102	26,692	3,078,410
Exercise of warrants and options, shares		2,669,223
Stock-based compensation	2,581,526	3,335	2,578,191
Stock-based compensation, shares		333,538
Net loss	-35,151,715			-35,151,715
Other comprehensive loss	-52,485				-52,485
Balance at Dec. 31, 2014	$41,196,156	$1,317,433	$249,032,066	($208,447,656)	($705,687)
Balance, shares at Dec. 31, 2014		131,743,365

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
Consolidated Statements of Cash Flows (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:
Net loss	($35,151,715)	($20,506,776)	($11,427,450)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,224,217	558,280	231,028
Loss on disposal of equipment, molds, furniture and fixtures	39,983		119,429
Stock-based compensation expense	2,624,742	2,435,260	2,025,532
Increase in inventory reserve	3,550,000
Amortization of premiums and discounts	20,036	210,057	66,324
Changes in operating assets and liabilities:
Accounts receivable	-2,478,494	1,198,643	310,813
Inventories	-2,948,873	-5,460,365	-118,365
Prepaid expenses and other current assets	-617,121	-1,222,962	-177,714
Deferred costs	-1,538,148	381,792	444,279
Other assets	545,059	-821,975	-18,012
Accounts payable	2,688,054	2,528,740	724,802
Accrued expenses and other current liabilities	221,086	2,534,293	687,297
Deferred revenue	5,487,873	3,196,862	-3,340,951
Net cash used in operating activities	-26,333,301	-14,968,151	-10,472,988
Cash flows from investing activities:
Proceeds from maturities of investments	24,000,000	24,000,000	12,000,000
Purchase of investments		-21,129,535	-30,166,239
Purchases of equipment, molds, furniture and fixtures	-4,663,313	-2,743,253	-3,256,632
Additions to patent rights	-989,790	-420,333	-244,761
Net cash provided by (used in) investing activities	18,346,897	-293,121	-21,667,632
Cash flows from financing activities:
Proceeds from issuance of common stock, net			53,328,188
Proceeds from exercise of warrants and stock options	3,105,102	2,326,838	11,579,413
Taxes paid from net share settlement of equity awards	-154,397	-104,329	-28,916
Net cash provided by financing activities	2,950,705	2,222,509	64,878,685
Effect of exchange rate changes on cash and cash equivalents	-2,648	8,935	1,067
Net increase (decrease) in cash and cash equivalents	-5,038,347	-13,029,828	32,739,132
Cash and cash equivalents:
Beginning of year	39,067,236	52,097,064	19,357,932
End of year	34,028,889	39,067,236	52,097,064
Noncash investing activities:
Purchases of equipment, molds, furniture and fixtures recorded in accounts payable and accrued expenses	1,118,925	985,365
Additions to patent rights recorded in accounts payable and accrued expenses	$949,631

Description_of_Business

Description of Business	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Description of Business	1	Description of Business
	Antares Pharma, Inc. (“Antares” or the “Company”) is an emerging, specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. Antares has numerous partnerships with pharmaceutical companies as well as multiple internal product development programs.
	The Company develops and manufactures for itself and with partners, novel, pressure-assisted injectors, with and without needles, which allow patients to self-inject drugs. Antares has developed variations of the needle-free injector by adding a small shielded needle to a pre-filled, single-use disposable injector, called the Vibex® pressure assisted auto injection system. This system is an alternative to the needle-free system for use with injectable drugs in unit dose containers and is suitable for branded and generic injectables. Antares also developed a disposable multi-dose pen injector for use with standard cartridges. The Company has entered into multiple licenses for these devices mainly in the United States (“U.S.”), Europe and Canada with Teva Pharmaceutical Industries, Ltd. (“Teva”).
	The Company has developed the Vibex® auto injector for its product OTREXUP™ (methotrexate) injection. In February 2014, Antares launched OTREXUP™ (methotrexate) injection, which is the first FDA-approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. OTREXUP™ is indicated for adults with severe active rheumatoid arthritis (“RA”), children with active polyarticular juvenile idiopathic arthritis (“pJIA”) and adults with severe recalcitrant psoriasis. To date, Antares has received FDA approval for dosage strengths of 7.5 mg, 10 mg, 15 mg, 20 mg and 25 mg of OTREXUP™. The Company has worldwide marketing rights for OTREXUP™ and commercializes OTREXUP™ on its own in the U.S. for the treatment of RA. The Company has provided LEO Pharma, Inc. (“LEO Pharma”) an exclusive license to commercialize OTREXUP™ in the U.S. for the treatment of psoriasis.
	The Company is currently conducting clinical studies of Vibex® QS T, for testosterone replacement therapy. On February 25, 2015, Antares announced positive top-line pharmacokinetic results that showed that the primary endpoint was achieved in the Company’s ongoing, multi-center, phase 3 clinical study (QST-13-003) evaluating the efficacy and safety of testosterone enanthate administered once-weekly by subcutaneous injection using the QuickShot® auto injector in testosterone deficient adult males. The Company also has initiated manufacturing development work for QS M, a combination product for an undisclosed central nervous system (“CNS”) indication.
	Antares also is developing VIBEX® Sumatriptan for the acute treatment of migraines which if approved will be sold by Teva. In January 2015, the Company received a complete response letter from FDA regarding its Abbreviated New Drug Application (“ANDA”) for VIBEX® Sumatriptan, providing revisions to labelling and citing minor deficiencies, and the Company submitted its response in March 2015.
	The Company’s development projects in collaboration with Teva include VIBEX® epinephrine, an exenatide multi-dose pen, and another undisclosed multi-dose pen. In December 2014, Teva submitted the final amendment to the VIBEX® epinephrine ANDA, and FDA accepted Teva’s filing of an ANDA in October 2014 for exenatide, formerly referred to as Teva “Pen 2”.
	The Company also makes a reusable, needle-free, spring-action injector device known as the Tjet® and Zomajet®, which is marketed for use with human growth hormone (“hGH”). Antares has had success in achieving distribution of our device for use with hGH through licenses to pharmaceutical partners, Ferring Pharmaceuticals BV (“Ferring”) and JCR Pharmaceuticals Co., Ltd. (“JCR”), and it has resulted in product sales and royalties. Ferring commercializes our needle-free injection system with their 4 mg and 10 mg hGH formulations marketed as Zomajet® 2 Vision and Zomajet® Vision X worldwide. Ferring purchased the U.S. rights to 5 mg Tev-Tropin from Teva in the fourth quarter of 2014. Tev-Tropin 10 mg is pending FDA approval. Distribution of growth hormone injectors occurs in the U.S., Europe, Japan and other Asian countries through our pharmaceutical company relationships.
	The Company also has a portfolio of gel-based products which are commercialized through various partners. Antares received FDA approval in December 2011 for an oxybutynin gel product, Gelnique 3%™, for the treatment of overactive bladder (“OAB”). The Company has a licensing agreement with Actavis plc (“Actavis”) under which Actavis is currently marketing Gelnique 3%™ in the U.S. Elestrin® (estradiol gel) is currently marketed by Meda Pharmaceuticals, Inc. (“Meda”) in the U.S. for the treatment of moderate-to-severe vasomotor symptoms associated with menopause.

Summary_of_Significant_Account

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements include the accounts of Antares Pharma, Inc. and its three wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

Certain prior year amounts have been reclassified in the consolidated financial statements to conform to the current year presentation. These reclassifications were made to present selling, general and administrative expenses in one line in the consolidated statements of operations. In prior years, sales and marketing expenses and general and administrative expenses were presented in separate lines. These reclassifications had no effect on previously reported net income or total operating expenses.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s significant accounting estimates relate to the revenue recognition periods for license revenues, OTREXUP™ revenue recognition based on estimated patient prescriptions dispensed, inventory valuation, valuation of equity instruments used in stock-based compensation, and determination of the fair value and recoverability of goodwill and patent rights. Actual results could differ from these estimates.

Foreign Currency Translation

The majority of the foreign subsidiaries revenues are denominated in U.S. dollars, and any required funding of the subsidiaries is provided by the U.S. parent. Nearly all operating expenses of the foreign subsidiaries, including labor, materials, leasing arrangements and other operating costs, are denominated in Swiss Francs. Additionally, bank accounts held by foreign subsidiaries are denominated in Swiss Francs, there is a low volume of intercompany transactions and there is not an extensive interrelationship between the operations of the subsidiaries and the parent company. As such, the Company has determined that the Swiss Franc is the functional currency for its foreign subsidiaries. The reporting currency for the Company is the United States Dollar (“USD”). The financial statements of the Company’s foreign subsidiaries are translated into USD for consolidation purposes. All assets and liabilities are translated using period-end exchange rates and statements of operations items are translated using average exchange rates for the period. The resulting translation adjustments are recorded as a separate component of stockholders’ equity, comprising all of the accumulated other comprehensive income (loss). Sales to certain customers by the U.S. parent are in currencies other than the U.S. dollar and are subject to foreign currency exchange rate fluctuations. Foreign currency transaction gains and losses are included in foreign exchange gain (loss) in the consolidated statements of operations.

Cash Equivalents

The Company considers highly liquid debt instruments with original maturities of 90 days or less to be cash equivalents.

Allowance for Doubtful Accounts

Trade accounts receivable are stated at the amount the Company expects to collect. The Company maintains allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. The Company considers the following factors when determining the collectability of specific customer accounts: customer credit-worthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms. At December 31, 2014, over 98% of the Company’s accounts receivable balance is due from OTREXUP™ distributors and its large pharmaceutical partners Teva and Ferring. Each of these companies has historically paid timely and has been financially stable organizations. Due to the nature of the accounts receivable balance, the Company believes the risk of doubtful accounts is minimal. If the financial condition of the Company’s customers were to deteriorate, adversely affecting their ability to make payments, additional allowances would be required. The Company provides for estimated uncollectible amounts through a charge to earnings and a credit to a valuation allowance. Balances that remain outstanding after the Company has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to accounts receivable. The Company recorded $37,000 of bad debt expense in 2014 and no bad debt expense in 2013 and 2012. The allowance for doubtful accounts balance was $10,000 at December 31, 2014 and 2013.

Inventories

Inventories are stated at the lower of cost or market. Cost is determined on a first-in, first-out basis. Certain components of the Company’s products are provided by a limited number of vendors, and the Company’s production and assembly operations are outsourced to third-party suppliers where substantially all of the Company’s inventory is located. Disruption of supply from key vendors or third-party suppliers may have a material adverse impact on the Company’s operations. The Company provides reserves for potentially excess, dated or obsolete inventories based on estimates of forecasted product demand and the likelihood of consumption in the normal course of business, considering the expiration dates of the inventories on hand, planned production volumes and lead times required for restocking of customer inventories. Although every effort is made to ensure that forecasts and assessments are reasonable, changes to these assumptions are possible. In such cases, estimates may prove inaccurate and result in an understatement or overstatement of the reserves required to fairly state such inventories. In connection with evaluation of OTREXUP™ inventory during 2014, the reserve for excess, dated or obsolete inventory was increased to $3,600,000 at December 31, 2014 from $50,000 at December 31, 2013.

Equipment, Molds, Furniture, and Fixtures

Equipment, molds, furniture, and fixtures are stated at cost and are depreciated using the straight-line method over their estimated useful lives ranging from three to ten years. Depreciation expense was $880,400, $359,471 and $145,775 for the years ended December 31, 2014, 2013 and 2012, respectively.

Goodwill

The Company has $1,095,355 of goodwill recorded as of December 31, 2014 that relates to the Minnesota reporting unit. The Company evaluates the carrying amount of goodwill on December 31 of each year and between annual evaluations if events occur or circumstances change that would more likely than not reduce the fair value of the Minnesota reporting unit below its carrying amount. Such circumstances could include, but are not limited to: (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, (3) an adverse action or assessment by a regulator, or (4) a sustained significant drop in the Company’s stock price. When evaluating whether goodwill is impaired, the Company compares the fair value of the Minnesota reporting unit to the carrying amount, including goodwill. If the carrying amount of the Minnesota reporting unit exceeded its fair value, then the amount of the impairment loss would be measured. The impairment loss would be calculated by comparing the implied fair value of goodwill to its carrying amount. In calculating the implied fair value of goodwill, the fair value of the Minnesota reporting unit would be allocated to all of its other assets and liabilities based on their fair values. The excess of the fair value of the Minnesota reporting unit over the amount assigned to its other assets and liabilities is the implied fair value of goodwill. An impairment loss would be recognized when the carrying amount of goodwill exceeds its implied fair value.

In evaluating whether the fair value of the Minnesota reporting unit was below its carrying amount, the Company used the market capitalization of the Company at December 31, 2014, which was approximately $339 million, to calculate an estimate of fair value of the Minnesota reporting unit. The Company determined that the percentage of the total market capitalization of the Company at December 31, 2014 attributable to the Minnesota reporting unit would have to be unreasonably low before the fair value of the Minnesota reporting unit would be less than its carrying amount. In making this determination, the Company evaluated the activity at the Minnesota reporting unit compared to the total Company activity, and considered the source and potential value of agreements currently in place, the source of recent product sales and development revenue growth, the source of total Company revenue and the source of cash generating activities. After performing the market capitalization analysis and concluding that the fair value of the Minnesota reporting unit was not below its carrying amount, the Company determined that no further detailed determination of fair value was required.

The Company’s evaluation of goodwill resulted in no impairment losses in 2014, 2013 and 2012.

Patent Rights

The Company capitalizes the costs of obtaining patent rights when there are projected future cash flows for marketed or partnered products associated with the patent. These capitalized costs are being amortized on a straight-line basis over the shorter of the life of the patent or the estimated useful life of the patent, which typically is over periods ranging from five to fifteen years beginning on the earlier of the date the patent is issued or the first commercial sale of product utilizing such patent rights.

The Company capitalizes external legal patent defense costs and costs for pursuing patent infringements when it determines that a successful outcome is probable and will lead to an increase in the value of the patent. The capitalized costs are amortized over the remaining life of the related patent. If changes in the anticipated outcome were to occur that reduce the likelihood of a successful outcome of the entire action to less than probable, the capitalized costs would be charged to expense in the period in which the change is determined. As of December 31, 2014 and 2013, approximately $1,800,000 and $100,000, respectively, of external legal patent costs were capitalized within patent rights, net.

Patent amortization expense for the years ended December 31, 2014, 2013 and 2012 was $343,817, $133,788 and $85,253, respectively, and is recorded in general and administrative expenses in the consolidated statements of operations.

Impairment of Long-Lived Assets and Long-Lived Assets to Be Disposed Of

Long-lived assets, including patent rights, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset or asset group. This analysis can be very subjective as the Company relies upon signed distribution or license agreements with variable cash flows to substantiate the recoverability of long-lived assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.

Each year the Company reviews patent costs for impairment and identifies patents related to products for which there are no signed distribution or license agreements or for which no revenues or cash flows are anticipated. In 2013, the Company recognized expense of $65,022 in connection with the write off of patent costs related to abandoned patents or patents no longer connected with current products. No impairment charges were recognized in 2014 or 2012. The gross carrying amount and accumulated amortization of patents, which are the only intangible assets of the Company subject to amortization, were $4,468,166 and $1,583,142, respectively, at December 31, 2014 and were $2,635,706 and $1,290,529, respectively, at December 31, 2013. The Company’s estimated aggregate patent amortization expense for the next five years is approximately $523,000, $539,000, $539,000, $539,000 and $314,000 in 2015, 2016, 2017, 2018 and 2019, respectively.

Fair Value of Financial Instruments

Cash and cash equivalents are stated at cost, which approximates fair value.

All short-term and long-term investments are U.S. Treasury bills or U.S. Treasury notes that are classified as held-to-maturity because the Company has the positive intent and ability to hold the securities to maturity. The securities are carried at their amortized cost. The fair value of all securities is determined by quoted market prices, which is a Level 1 fair value measurement. All long-term investments mature in less than two years. At December 31, 2014 the short-term investments had a fair value of $6,005,040 and a carrying value of $6,002,438. At December 31, 2013 the short-term investments had a fair value of $24,021,522 and a carrying value of $24,014,305 and the long-term investments had a fair value of $6,007,851 and a carrying value of $6,008,169.

Revenue Recognition

The Company recognizes revenue from the sale of products and from license fees, milestones and royalties. Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred and title has passed, (iii) the price is fixed or determinable and (iv) collectability is reasonably assured.

Otrexup Revenue Recognition

In February 2014, the Company began detailing OTREXUP™ to health care professionals in the U.S. and began shipping to wholesale pharmaceutical distributors, subject to rights of return within a period beginning six months prior to, and ending 12 months following, product expiration. Given the limited sales history of OTREXUP™, the Company currently cannot reliably estimate expected returns of the product at the time of shipment. Accordingly, recognition of revenue is deferred on product shipments of OTREXUP™ until the right of return no longer exists, which occurs at the earlier of the time OTREXUP™ units are dispensed through patient prescriptions or expiration of the right of return. Units dispensed are generally not subject to return, except in the rare cases where the product malfunctions or the product is damaged in transit. Patient prescriptions dispensed are estimated using third-party market prescription data. These third-party sources poll pharmacies, hospitals, mail order and other retail outlets for OTREXUP™ prescriptions and project this sample on a national level. If patient prescriptions dispensed for a given period are underestimated or overestimated, adjustments to revenue may be necessary in future periods.

The Company recognized $7,309,603 in OTREXUP™ product revenue, which is net of estimated wholesaler discounts, prompt pay discounts, chargebacks, rebates and patient discount programs. A deferred revenue balance of $1,061,947 was recorded at December 31, 2014 for OTREXUP™ product shipments, which is net of estimated wholesaler discounts, prompt pay discounts, chargebacks, rebates and patient discount programs.

The Company will continue to recognize revenue upon the earlier to occur of prescription units dispensed or expiration of the right of return until there has been sufficient history to estimate product returns. When it becomes possible to reasonably estimate product returns, a one-time increase in net revenue will be recorded to recognize revenue previously deferred, net of appropriate allowances for estimated wholesaler discounts, prompt pay discounts, chargebacks, rebates and patient discount programs.

Product Sales Allowances

The Company recognizes product sales allowances as a reduction of product sales in the same period the related revenue is recognized. Product sales allowances are based on amounts owed or to be claimed on the related sales. These estimates take into consideration the terms of our agreements with customers and third-party payors and the levels of inventory within the distribution channels that may result in future rebates or discounts taken. In certain cases, such as patient support programs, the Company recognizes the cost of patient discounts as a reduction of revenue based on estimated utilization. If actual future results vary, it may be necessary to adjust these estimates, which could have an effect on product revenue in the period of adjustment. Product sales allowances include:

Wholesaler Distribution Fees. Distribution fees are paid to certain wholesale distributors based on contractually determined rates. The Company accrues the fee on shipment to the respective wholesale distributors and recognizes the fee as a reduction of revenue in the same period the related revenue is recognized.

Prompt Pay Discounts. The Company offers cash discounts to its customers, generally 2% of the sales price, as an incentive for prompt payment. The Company accounts for cash discounts by reducing accounts receivable by the prompt pay discount amount and recognizes the discount as a reduction of revenue in the same period the related revenue is recognized.

Chargebacks. Through December 31, 2014, the Company has been subject to a minimal amount of chargebacks. The Company expects to provide discounts primarily to authorized users of the Federal Supply Schedule (“FSS”) of the General Services Administration under an FSS contract negotiated by the Department of Veterans Affairs and various organizations under Medicaid contracts and regulations. These entities purchase products from the wholesale distributors at a discounted price, and the wholesale distributors then charge back to the Company the difference between the current wholesale acquisition cost and the price the entity paid for the product. The Company will estimate and accrue chargebacks based on estimated wholesaler inventory levels, current contract prices and historical chargeback activity. Chargebacks are recognized as a reduction of revenue in the same period the related revenue is recognized.

Rebates. The Company participates in certain rebate programs, which provide discounted prescriptions to qualified insured patients. As of December 31, 2014, rebates have been primarily related to Medicare and Medicaid programs. Under these rebate programs, the Company will pay a rebate to the third-party administrator of the program, generally two to three months after the quarter in which prescriptions subject to the rebate are filled. The Company estimates and accrues for these rebates based on current contract prices, historical and estimated future percentages of product sold to qualified patients. Rebates are recognized as a reduction of revenue in the same period the related revenue is recognized.

Patient Discount Programs. The Company offers discount card programs to patients for OTREXUP™ in which patients receive discounts on their prescriptions that are reimbursed by the Company. The Company estimates the total amount that will be redeemed based on historical redemption experience and on levels of inventory in the distribution and retail channels and recognizes the discount as a reduction of revenue in the same period the related revenue is recognized.

Other Revenue Recognition

The Company sells its proprietary reusable needle-free injectors and related disposable products to pharmaceutical partners and through medical product distributors. The Company’s reusable injectors and related disposable products are not interchangeable with any competitive products and must be used together. The Company recognizes revenue upon shipment when title transfers. The Company offers no price protection or return rights other than for customary warranty claims. Sales terms and pricing are governed by license and distribution agreements.

Revenue arrangements with multiple deliverables are divided into separate units of accounting if certain criteria are met, including whether the deliverable has stand-alone value to the customer, the customer has a general right of return relative to the delivered item and delivery or performance of the undelivered item is probable and substantially within the vendor’s control. Arrangement consideration is allocated at the inception of the arrangement to all deliverables on the basis of their relative selling price. The selling price for each deliverable is determined using: (i) vendor-specific objective evidence of selling price (“VSOE”), if it exists, (ii) third-party evidence of selling price (“TPE”) if VSOE does not exist, and (iii) the Company’s best estimate of the selling price if neither VSOE nor TPE exists. For transactions entered into prior to January 1, 2011, revenue is recognized for each deliverable based upon the applicable revenue recognition criteria discussed above and upon acceptance of goods or performance of service. Effective January 1, 2011, for new or significantly modified transactions, the Company allocates revenue consideration, excluding contingent consideration, based on the relative selling prices of the separate units of accounting contained within an arrangement containing multiple deliverables.

Royalty revenues are recognized in the quarter earned when the Company has information available to determine the royalty amount, however, the majority of the Company’s royalty revenues are recognized one quarter in arrears as information is typically not available to determine quarterly royalty earnings until royalty statements are received from partners.

At December 31, 2014, $10,807,596 of non-refundable cash payments received have been recorded as deferred revenue in cases where the revenue is not immediately recognized due to the earnings process not yet having been completed.

Shipping and Handling Costs

The Company records shipping and handling costs in cost of product sales.

Share-Based Compensation

The Company utilizes share based compensation in the form of stock options, restricted stock units (“RSUs”) and performance-based restricted stock units (“PSUs”). The Company records compensation expense associated with share based awards granted to employees at the fair value of the award on the date of grant. The Company uses the Black-Scholes option valuation model to determine the fair value of stock options. The fair values of RSU and PSU grants containing service or performance conditions are based on the market value of the Company’s Common Stock on the date of grant. The fair value of PSUs containing a market condition are estimated using a Monte Carlo simulation. Pre-vesting forfeitures are estimated in the determination of total stock-based compensation cost based on Company experience. The value of the portion of the award that is ultimately expected to vest is expensed ratably over the requisite service period as compensation expense in the consolidated statement of operations. The determination of fair value of share-based payment awards on the grant date requires significant judgment. Assumptions concerning the Company’s stock price volatility and projected employee exercise behavior over the contractual life of the award can significantly impact the estimated fair value of an award. Given the Company’s limited history, such assumptions may not be reflective of the patterns that will ultimately be experienced.

Product Warranty

The Company provides a warranty on its reusable needle-free injector devices. Warranty terms for these devices sold to end-users by dealers and distributors are included in the device instruction manual included with each device sold. Warranty terms for these devices sold to pharmaceutical partners who provide their own warranty terms to end-users are included in the contracts with the pharmaceutical partners. The Company is obligated to repair or replace, at the Company’s option, a needle-free injector device found to be defective due to use of defective materials or faulty workmanship. The warranty does not apply to any product that has been used in violation of instructions as to the use of the product or to any product that has been neglected, altered, abused or used for a purpose other than the one for which it was manufactured. The warranty also does not apply to any damage or defect caused by unauthorized repair or the use of unauthorized parts. The warranty period on a needle-free injector device is typically 24 months from either the date of retail sale of the device by a dealer or distributor or the date of shipment to a customer if specified by contract. The Company recognizes the estimated cost of warranty obligations at the time the products are shipped based on historical claims incurred by the Company. Actual warranty claim costs could differ from these estimates. Warranty liability activity is as follows:

Balance at

Provisions

Claims

Balance at

Beginning of

End of

Year

2014

100,000

5,100

(5,100

)

100,000

2013

100,000

50,819

(50,819

)

100,000

2012

100,000

72,893

(72,893

)

100,000

Research and Development

Research and development costs are expensed as incurred. In December 2014, the Company received an invoice from the FDA in the amount of $970,840 for user fees related to OTREXUP™ for the twelve month period ending September 30, 2014 for which approximately $243,000 should have been recorded for the year ended December 31, 2013. The Company had not previously recorded the expense associated with this invoice and the full amount was recorded in research and development expenses in the fourth quarter of 2014. The Company has evaluated this out of period adjustment and has determined that it is not material to the Company’s financial position or results of operations for 2013 or 2014.

Income Taxes

Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. As of December 31, 2012, a valuation allowance was established to offset all of the Company’s net deferred tax assets, and as of December 31, 2013, a valuation allowance was established to offset all of the U.S. net deferred tax assets. For the year ended December 31, 2013, the Company determined it was more likely than not that a portion of the deferred tax assets would be realized and recorded an income tax benefit of $300,000 after releasing $300,000 of the valuation allowance related to the Switzerland deferred tax assets. For the year ended December 31, 2014, the Company recorded income tax expense related to the Swiss operations of $25,000, reducing deferred tax assets to $275,000 at December 31, 2014.

Net Loss Per Share

Basic net loss per share is computed by dividing net income or loss available to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed similar to basic net loss per share except that the weighted average shares outstanding are increased to include additional shares from the assumed exercise of stock options and warrants, if dilutive. The number of additional shares is calculated by assuming that outstanding stock options or warrants were exercised and that the proceeds from such exercise were used to acquire shares of common stock at the average market price during the reporting period. All potentially dilutive common shares were excluded from the calculation because they were anti-dilutive for all periods presented. Potentially dilutive securities at December 31, 2014, 2013 and 2012, excluded from dilutive loss per share as their effect is anti-dilutive, are as follows:

2014

2013

2012

Stock options and warrants

7,245,485

8,242,992

10,830,530

Recent Accounting Pronouncements

In July 2013, the FASB issued Accounting Standards Update 2013-11, “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists” (“ASU 2013-11”). ASU 2013-11 amends accounting guidance on the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or tax credit carryforward exists. This new guidance requires entities, if certain criteria are met, to present an unrecognized tax benefit, or portion of an unrecognized tax benefit, in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward when such items exist in the same taxing jurisdiction. The adoption of ASU 2013-11 is expected to reduce diversity in practice by providing guidance on the presentation of unrecognized tax benefits. The provisions of ASU 2013-11 are effective for fiscal years and interim periods beginning after December 15, 2013. The adoption of this update in the first quarter of 2014 did not have a material effect on the Company’s consolidated financial statements.

Composition_of_Certain_Financi

Composition of Certain Financial Statement Captions	12 Months Ended
Composition of Certain Financial Statement Captions	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Composition of Certain Financial Statement Captions	3	Composition of Certain Financial Statement Captions


			December 31,			December 31,
			2014			2013
	Inventories:
	Raw material		$	461,396		$	1,056,054
	Work in process			3,896,837			3,034,321
	Finished goods			1,501,691			2,370,676

			$	5,859,924		$	6,461,051


	Equipment, molds, furniture and fixtures:
	Furniture, fixtures and office equipment		$	1,551,100		$	1,501,612
	Production molds and equipment			8,322,631			7,389,062
	Molds and tooling in process			3,836,650			424,521
	Less accumulated depreciation			(2,881,640	)		(2,362,944	)

			$	10,828,741		$	6,952,251


	Patent rights:
	Patent rights		$	4,468,166		$	2,635,706
	Less accumulated amortization			(1,583,142	)		(1,290,529	)

			$	2,885,024		$	1,345,177


	Accrued expenses and other liabilities:
	Accrued employee compensation and benefits		$	1,559,255		$	2,348,456
	Liabilities related to OTREXUP™ commercialization and development expenses			1,922,422			1,946,869
	OTREXUP™ reserves for discounts, rebates, allowances			230,768			—
	Other liabilities			1,923,114			1,157,750

			$	5,635,559		$	5,453,075

Leases

Leases	12 Months Ended
Leases	Dec. 31, 2014
Leases [Abstract]
Leases	4	Leases
	The Company has non-cancelable operating leases for its corporate headquarters facility in Ewing, New Jersey, and its office, research and development facility in Plymouth, MN, a suburb of Minneapolis, MN. In December 2013, the Company entered into a lease agreement for approximately 18,000 square feet of office, research and development space in a new Plymouth location, which the Company occupied in April 2014. The leases require payment of all executory costs such as maintenance and property taxes. Rent expense incurred for the years ended December 31, 2014, 2013 and 2012 was $611,818, $453,142 and $325,971, respectively. Future minimum lease payments under operating leases with remaining terms in excess of one year as of December 31, 2014 were as follows:


			Amount
	2015		$	594,806
	2016			599,539
	2017			611,067
	2018			622,716
	2019			565,955
	Thereafter			530,993

	Total future minimum lease payments		$	3,525,076

Income_Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	5	Income Taxes
	The Company was subject to taxes in both the U.S. and Switzerland in each of the years in the three-year period ended December 31, 2014. In the U.S., the Company incurred losses for both book and tax purposes for the year ended December 31, 2014, and, accordingly, no income taxes were provided. In Switzerland, net operating loss carryforwards were used to fully offset taxable income of approximately $200,000, $500,000 and $5,500,000 in the years ended December 31, 2014, 2013 and 2012, respectively.
	Income (loss) before income taxes was derived from the following jurisdictions:


			2014			2013			2012
	U.S.		$	(35,359,378	)	$	(21,568,727	)	$	(16,477,710	)
	Switzerland			232,663			761,951			5,050,260

			$	(35,126,715	)	$	(20,806,776	)	$	(11,427,450	)

	Effective tax rates differ from statutory income tax rates in the years ended December 31, 2014, 2013 and 2012 as follows:


			2014			2013			2012
	Statutory income tax rate			(34.0	)%		(34.0	)%		(34.0	)%
	State income taxes			(3.7	)		(1.0	)		(3.6	)
	Valuation allowance increase (decrease)			37.8			28.8			29.8
	Effect of foreign operations			(0.2	)		(0.7	)		(8.5	)
	Change in unused net operating loss and credit carryforwards			(0.2	)		(1.0	)		14
	Nondeductible items			0.4			6.5			0.6
	Other			—			—			1.7

				0.1	%		(1.4	)%		0	%


	Deferred tax assets (liabilities) as of December 31, 2014 and 2013 consist of the following:


			2014			2013
	Gross deferred tax assets:
	Net operating loss carryforward – U.S.		$	40,428,000		$	28,832,000
	Net operating loss carryforward – Switzerland			3,128,000			4,556,000
	Research and development tax credit carryforward			3,617,000			2,589,000
	Deferred revenue			1,292,000			320,000
	Stock-based compensation			1,677,000			1,581,000
	Inventory reserve			1,356,000			18,000
	Compensation accruals			425,000			38,000
	Other			41,000			37,000

				51,964,000			37,971,000
	Gross deferred tax liabilities - depreciation and amortization			(648,000	)		(105,000	)
	Less valuation allowance			(51,041,000	)		(37,566,000	)

	Net deferred tax asset		$	275,000		$	300,000

	The valuation allowance for deferred tax assets as of December 31, 2014 and 2013 was $51,041,000 and $37,566,000, respectively. The total valuation allowance increased $13,475,000 for the year ended December 31, 2014 and increased $5,076,000 for the year ended December 31, 2013.
	In 2013, management determined it was more likely than not that a portion of the deferred tax assets associated with NOL carryforwards in Switzerland will be realized; therefore, $300,000 of the valuation allowance was released as of December 31, 2013. This determination was made after considering that the Switzerland operations had generated taxable income for two consecutive years, 2013 and 2012, and after determining that it appeared likely that taxable income would continue in future years. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences become deductible or in which net operating loss or tax credit carryforwards can be utilized. Both positive and negative evidence is considered in assessing the realizability of deferred tax assets and determining whether or not to record a valuation allowance. In 2014, the Switzerland operations generated taxable income of approximately $200,000 and the Company recognized tax expense of $25,000, realizing the benefit of $25,000 of deferred tax assets associated with NOL carryforwards in Switzerland.
	After considering the evidence with respect to the U.S. deferred tax assets, management determined that as of December 31, 2014, it continues to be more likely than not that the U.S. deferred tax assets will not be realized and has recorded a valuation allowance against all U.S. deferred tax assets.
	The Company has a U.S. federal net operating loss carryforward at December 31, 2014, of approximately $116,800,000, which, subject to limitations of Internal Revenue Code (“IRC”) Section 382, is available to reduce income taxes payable in future years. If not used, this carryforward will expire in years 2018 through 2034. Included in the federal net operating loss is approximately $5,600,000 of loss generated by deductions related to equity-based compensation, the tax effect of which will be recorded to additional paid in capital when utilized. Additionally, the Company has research credit carryforwards of approximately $3,600,000. These credits expire in years 2018 through 2034.
	Utilization of U.S. net operating losses and tax credits of the Company may be subject to annual limitations under IRC Sections 382 and 383, respectively. The annual limitations, if any, have not yet been determined. When a review is performed and if any annual limitations are determined, then the gross deferred tax assets for the net operating losses and tax credits would be reduced with a reduction in the valuation allowance of a like amount.
	The Company also has a Swiss net operating loss carryforward at December 31, 2014, of approximately $23,200,000, which is available to reduce income taxes payable in future years. If not used, this carryforward will expire in years 2015 through 2018, with approximately $22,700,000 expiring over the next three years.


	As of December 31, 2014 and 2013, there were no unrecognized tax benefits. Accordingly, a tabular reconciliation from beginning to ending periods is not provided. The Company will classify any future interest and penalties as a component of income tax expense if incurred. To date, there have been no interest or penalties charged or accrued in relation to unrecognized tax benefits.
	The Company does not anticipate that the total amount of unrecognized tax benefits will change significantly in the next twelve months.
	The Company is subject to federal and state examinations for the years 2009 and thereafter. There are no tax examinations currently in progress.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
Stockholders' Equity	Dec. 31, 2014
Equity [Abstract]
Stockholders' Equity	6	Stockholders’ Equity
	Common Stock
	In October 2012, the Company sold 12,500,000 shares of common stock at a price of $4.00 per share in a public offering, and in November 2012 the Company sold 1,759,868 shares of the Company’s common stock at $4.00 per share as a result of the partial exercise of the underwriters’ over-allotment option. The Common Stock sales resulted in net proceeds of $53,328,188 after deducting offering expenses of $3,711,284.
	Stock Options
	The Company’s 2008 Equity Compensation Plan (the “Plan”) allows for grants in the form of incentive stock options, nonqualified stock options, stock units, stock awards, stock appreciation rights, and other stock-based awards. All of the Company’s officers, directors, employees, consultants and advisors are eligible to receive grants under the Plan. Under the Plan, the maximum number of shares authorized for issuance is 21,000,000 and the maximum number of shares of stock that may be granted to any one participant during a calendar year is 1,000,000 shares. Options to purchase shares of common stock are granted at exercise prices not less than 100% of fair market value on the dates of grant. The term of each option is 10 years and the options typically vest in quarterly installments over a three-year period. As of December 31, 2014, the Plan had 4,250,074 shares available for grant. Stock option exercises are satisfied through the issuance of new shares.
	A summary of stock option activity under the Plan as of December 31, 2014 and the changes during the three years then ended is as follows:


			Number of				Weighted				Weighted				Aggregate
			Shares				Average				Average				Intrinsic Value
							Exercise Price				Remaining				($)
							($)				Contractual
											Term (Years)
	Outstanding at December 31, 2011			7,785,672				1.21
	Granted/Issued			1,334,731				3.18
	Exercised			(1,164,636	)			1.2								2,620,360
	Cancelled/Forfeited			(141,206	)			4.06

	Outstanding at December 31, 2012			7,814,561				1.49
	Granted/Issued			1,129,380				3.99
	Exercised			(981,385	)			0.72								3,319,471
	Cancelled/Forfeited			(264,664	)			3.48

	Outstanding at December 31, 2013			7,697,892				1.89
	Granted/Issued			2,596,201				2.89
	Exercised			(2,124,123	)			1.21								3,585,453
	Cancelled/Forfeited			(924,485	)			3.41

	Outstanding at December 31, 2014			7,245,485				2.25				6.7				4,640,730

	Exercisable at December 31, 2014			4,876,651				1.87				5.4				4,461,950


	As of December 31, 2014, there was approximately $3,400,000 of total unrecognized compensation cost related to nonvested outstanding stock options that is expected to be recognized over a weighted average period of approximately 2.2 years.
	Stock option expense recognized in 2014, 2013 and 2012 was approximately $2,060,000, $1,364,000 and $1,164,000, respectively. The per share weighted average fair value of options granted during 2014, 2013 and 2012 was estimated as $1.64, $2.26, $1.64, respectively, on the date of grant using the Black-Scholes option pricing model based on the assumptions noted in the table below. Expected volatilities are based on the historical volatility of the Company’s stock. The weighted average expected life is based on both historical and anticipated employee behavior.


			December 31,
			2014				2013				2012
	Risk-free interest rate			1.6	%			0.9	%			0.7	%
	Annualized volatility			60.7	%			62	%			61	%
	Weighted average expected life, in years			6				6				5
	Expected dividend yield			0	%			0	%			0	%
	Option exercises during 2014, 2013 and 2012 resulted in proceeds of $2,564,987, $692,348 and $792,203, respectively, and in the issuance of shares of common stock of 2,124,123 in 2014, 981,385 in 2013 and 965,597 in 2012. In 2012, 583,344 options were exercised under a cashless provision resulting in the issuance of 384,305 shares of common stock and no cash proceeds to the Company.
	Stock Awards
	The employment agreements with certain members of executive management included performance-based incentives under which the executives could be awarded shares of common stock upon the occurrence of various triggering events. As of December 31, 2013, the time period for these potential awards had expired. There were 35,000 shares awarded under these agreements in 2012.
	At times, the Company makes discretionary grants of its common stock to members of management and other employees in lieu of cash bonus awards or in recognition of special achievements. In 2014, there were 150,000 shares of common stock granted to members of executive management as bonus compensation for achievements in 2013. There were no discretionary grants of common stock in 2013, and grants in 2012 totaled 60,000.
	Expense is recognized on a straight line basis over the vesting period and is based on the fair value of the stock on the grant date. The fair value of each stock award is determined based on the number of shares granted and the market price of the Company’s common stock on the date of grant. Expense recognized in connection with performance and discretionary stock awards was $8,722 and $301,017 in 2013 and 2012, respectively.
	In addition to the shares granted to members of management and employees, at times directors receive a portion of their annual compensation in shares of Company common stock. In 2014, no shares were granted to the directors, as all directors’ compensation was paid in cash and stock options. Expense is recognized on a straight line basis over the one year period that the compensation is earned. Expense recognized in connection with shares granted to directors was $356,000, $679,500 and $560,000 in 2014, 2013 and 2012, respectively.
	Long Term Incentive Program
	The Company’s Board of Directors has approved a long term incentive program (“LTIP”) for the benefit of the Company’s senior executives. Pursuant to the LTIP, the Company’s senior executives have been awarded stock options and performance stock units (“PSU”) with targeted values based on values granted by the Company’s peer group. In 2014, the program was modified such that the value of the annual award for each senior executive was delivered 50% in the form of PSUs, 25% in the form of shares of restricted stock units (“RSU”) and 25% in the form of stock options. In the prior year, 33% of the value for each senior executive was delivered in the form of stock options, 33% of the value was delivered in the form of PSUs and 33% was delivered in the form of RSUs. The stock options have a ten-year term, have an exercise price equal to the closing price of the Company’s common stock on the date of grant, vest in quarterly installments over three years, were otherwise granted on the same standard terms and conditions as other stock options granted pursuant to the Plan and are included in the stock options table above. The RSUs vest in three equal annual installments. Expense recognized in 2014 and 2013 in connection with the RSUs was approximately $212,000 and $125,000, respectively. The PSU awards made to the senior executives will be vested and convert into actual shares of the Company’s common stock based on the Company’s attainment of certain performance goals over a performance period of three years. In connection with PSU awards for defined performance goals considered probable of achievement, a net expense reduction of $3,000 was recognized in 2014. The net expense reduction was primarily the result of the reversal of expense associated with awards previously granted to senior executives who left the Company in 2014 where the awards will not vest. Expense recognized in 2013 in connection with the PSUs for defined performance goals considered probable of achievement was $259,000.
	The 2014 awards included PSUs that will be earned based on the Company’s total shareholder return (“TSR”) as compared to the Nasdaq Biotechnology Index (“NBI”) at the end of the performance period, which performance period is January 1, 2014 to December 31, 2016. These PSUs were granted with a grant date fair value of $2.64. The fair value of the target number of shares that can be earned is being recognized as compensation expense over the performance period, and expense of $66,280 was recognized in connection with this award in 2014. Depending on the outcome of the performance goal, a recipient may ultimately earn a number of shares greater or less than their target number of shares granted, ranging from 0% to 150% of the PSUs granted.
	The fair value of the TSR PSUs granted in 2014 was determined using a Monte Carlo simulation and utilized the following inputs and assumptions:


	Closing stock price on grant date		$	3.09
	Performance period starting price		$	4.08
	Term of award (in years)			2.59
	Volatility			50.87	%
	Risk-free interest rate			0.61	%
	Expected dividend yield			0	%
	Fair value per TSR PSU		$	2.64
	The performance period starting price is measured as the average closing price over the last 20 trading days prior to the performance period start. The Monte Carlo simulation model also assumed correlations of returns of the prices of the Company’s common stock and the common stocks of the NBI companies and stock price volatilities of the NBI companies.
	The performance stock unit awards and restricted stock granted under the long term incentive program are summarized in the following table:


		Performance Stock Units								Restricted Stock
		Number of				Weighted				Number of				Weighted
		Shares				Average Fair				Shares				Average Fair
						Value ($)								Value ($)
Outstanding at December 31, 2011			182,000				1.66				—				—
Granted			137,715				4.26				—				—
Vested			—				—				—				—
Forfeited/Expired			—				—				—				—

Outstanding at December 31, 2012			319,715				2.78				—				—
Granted			185,185				3.96				185,185				3.96
Vested			—				—				—				—
Forfeited/Expired			(98,237	)			3.32				(29,461	)			3.96

Outstanding at December 31, 2013			406,663				3.19				155,724				3.96
Granted			651,980				3.02				325,991				3.02
Vested			(87,519	)			2.03				(51,907	)			3.96
Forfeited/Expired			(507,582	)			3.26				(198,684	)			3.45

Outstanding at December 31, 2014			463,542				3.08				231,124				3.07

A portion of the shares that were granted as discretionary shares or under the LTIP that vested in 2014, 2013 and 2012 were net-share settled such that the Company withheld shares with value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. The total shares withheld were 38,768, 30,153 and 11,165 in 2014, 2013 and 2012, respectively, and were based on the value of the shares on their vesting date as determined by the Company’s closing stock price. Total payments for the employees’ tax obligations to the taxing authorities were $154,397, $104,329 and $28,916 in 2014, 2013 and 2012, respectively, and are reflected as a financing activity within the Consolidated Statements of Cash Flows. These net-share settlements had the effect of share repurchases by the Company as they reduced the number of shares that would have otherwise been issued as a result of the vesting and did not represent an expense to the Company.
Warrants
Warrant activity is summarized as follows:


		Number of				Weighted
		Shares				Average Price ($)
Outstanding at December 31, 2011			10,075,284				1.66
Exercised			(7,056,075	)			1.53
Cancelled			(3,240	)			2

Outstanding at December 31, 2012			3,015,969				1.98
Exercised			(1,470,869	)			1.11
Cancelled			(1,000,000	)			3.78

Outstanding at December 31, 2013			545,100				1
Exercised			(545,100	)			1

Outstanding at December 31, 2014			—

Warrant exercises during 2014, 2013 and 2012 resulted in proceeds of $545,115, $1,634,490 and $10,787,210, respectively, and in the issuance of 545,100, 1,470,869 and 7,056,075 shares of common stock, respectively.

Employee_401k_Savings_Plan

Employee 401(k) Savings Plan	12 Months Ended
	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
Employee 401(k) Savings Plan	7	Employee 401(k) Savings Plan
	The Company sponsors a 401(k) defined contribution retirement savings plan that covers all U.S. employees who have met minimum age and service requirements. Under the plan, eligible employees may contribute up to 50% of their annual compensation into the plan up to the IRS annual limits. At the discretion of the Board of Directors, the Company may contribute elective amounts to the plan, allocated in proportion to employee contributions to the plan, employee’s salary, or both. For the years ended December 31, 2014, 2013 and 2012, the total number of employees enrolled in the plan has increased and the Company elected to make contributions to the plan totaling approximately $373,000, $230,000 and $173,000, respectively.

License_Agreements

License Agreements	12 Months Ended
	Dec. 31, 2014
Deferred Revenue Disclosure [Abstract]
License Agreements	8	License Agreements

	Development and License Agreement

	In September 2014 the Company entered into a development and license agreement with an undisclosed pharmaceutical partner, under which the Company will develop and supply an auto injector product for delivery of an undisclosed drug. Under the agreement, an upfront payment, development milestones, and royalties on the partner’s product sales, as well as a purchase price for each device sold are to be received by the Company. The Company identified and evaluated a number of deliverables in the agreement and concluded that the manufacturing deliverable has stand-alone value but the license and development work do not have value on a stand-alone basis. As a result, the license and development deliverables do not qualify for treatment as separate units of accounting. Accordingly, the license and development deliverables will be accounted for as a single unit of accounting and will be recognized as revenue during the estimated development period. The Company recognized revenue in 2014 of approximately $560,000 and recorded deferred revenue of $115,000 at December 31, 2014 in connection with this agreement.

	LEO Pharma Promotion and License Agreement

	In November 2013 the Company entered into a promotion and license agreement with LEO Pharma. Under this agreement the Company granted LEO Pharma the exclusive right to promote OTREXUP™ to dermatologists for symptomatic control of severe recalcitrant psoriasis in adults in the U.S. LEO Pharma is responsible for promotion and marketing activities in dermatology and the Company is responsible for the supply of OTREXUP™ product and samples. The Company received from LEO Pharma a non-refundable upfront payment of $5.0 million, a milestone payment of $5.0 million and will receive a milestone payment of $10.0 million upon realizing a defined level of net sales in a calendar year. The Company will pay LEO Pharma a percentage of net sales generated in dermatology and will record the payments to LEO Pharma as sales and marketing expense.

	The Company identified and evaluated a number of deliverables in the agreement and concluded that none of the deliverables have value on a stand-alone basis. As a result, these deliverables do not qualify for treatment as separate units of accounting. Accordingly, the deliverables have been accounted for as a single unit of accounting and each of the payments will be allocated to these deliverables and will be recognized as revenue over the 35 month estimated life of the agreement. The Company recognized revenue of $3,429,000 and $571,000 in the years ended December 31, 2014 and 2013, respectively, and recorded deferred revenue of $6,000,000 at December 31, 2014.

	Teva License Development and Supply Agreements

	In November 2012, the Company entered into a license, supply and distribution agreement with Teva for an auto injector product containing sumatriptan for the treatment of migraines. Teva will manufacture and supply sumatriptan in a prefilled syringe. The Company will manufacture the device, assemble the device and prefilled syringe and supply the final product to Teva for distribution. Teva will distribute the product in the United States. Teva also received an option for rights in other territories. Under the agreement, the Company received an upfront payment, which was deferred, and will receive a milestone payment upon commercial launch. In addition, net profits will be split 50/50 between the Company and Teva. The term of the agreement is seven years from commercial launch, with automatic one year renewals.



	In December 2007, the Company entered into a license, development and supply agreement with Teva under which the Company will develop and supply a disposable pen injector for use with two undisclosed patient-administered pharmaceutical products. Under the agreement, an upfront payment, development milestones, and royalties on Teva’s product sales, as well as a purchase price for each device sold are to be received by the Company under certain circumstances. Based on an analysis under accounting literature applicable at the time of the agreement, the entire arrangement was considered a single unit of accounting. Therefore, payments received and development costs incurred were deferred and were to be recognized from the start of manufacturing through the end of the initial contract period. In January 2011, this license, development and supply agreement was amended wherein Teva pays for all development work and tooling associated with device development. Additionally, the Company is now developing two different disposable pens, one for each product. The Company determined that the changes to the agreement as a result of the amendment was a material modification to the agreement and the accounting for the revenue and costs under this agreement was changed. For the year ended December 31, 2012, the accounting change resulting from the material modification resulted in recognition of licensing revenue previously deferred of $62,225. This agreement will continue until the later of December 2017 or the expiration date of the last to expire patent covering the device or product that is filed no later than 12 months after FDA approval, and will be automatically renewed for successive periods of two years each.

	In September 2006, the Company entered into a Supply Agreement with Teva. Pursuant to the agreement, Teva is obligated to purchase all of its needle-free delivery device requirements from Antares for hGH to be marketed in the United States. Antares was entitled to an upfront cash payment, milestone fees and royalty payments on Teva’s net sales, as well as a purchase price for each device sold. The upfront payment was recognized as revenue over the development period. The milestone fees and royalties will be recognized as revenue when earned. In 2009, Teva launched the Company’s Tjet needle-free device with their hGH Tev-Tropin®. In 2010, the Company received a milestone payment from Teva in connection with this agreement. The original term of this agreement extended through September 2013. In May 2013 the agreement was amended to provide for one year automatic renewals unless terminated by either party six months ahead of the expiring term. In the fourth quarter of 2014, Teva sold the U.S. rights to 5 mg Tev-Tropin to Ferring. Tev-Tropin 10 mg is pending FDA approval.

	In July 2006, the Company entered into an exclusive License Development and Supply Agreement with Teva. Pursuant to the agreement, Teva is obligated to purchase all of its delivery device requirements from Antares for an auto injector product containing epinephrine to be marketed in the U.S. and Canada. Antares was entitled to an upfront cash payment, milestone fees, a negotiated purchase price for each device sold, as well as royalties on sales of their product. This agreement will continue until the later of July 2016 or the expiration date of the last to expire patent covering the device or product that is filed no later than 12 months after FDA approval.

	On April 26, 2012, the Company announced that Meridian Medical Technologies, a Pfizer subsidiary, entered into a settlement agreement with Teva that will resolve pending patent litigation related to its abbreviated new drug application (ANDA) for a generic epinephrine auto-injector. According to the terms of the settlement, Teva may launch a generic epinephrine auto-injector covered by its ANDA on June 22, 2015 or earlier under certain circumstances, subject to receipt of approval from the U.S. Food and Drug Administration. Additional terms of the agreement are confidential.

	Under a separate agreement, Teva has agreed to provide the Company with device orders of an undisclosed amount in the years 2013 and 2014, to make a milestone payment to the Company upon FDA approval of epinephrine auto-injector, and to assume all litigation costs related to the patent litigation between Teva and Meridian Medical.

	Ferring Agreements

	On November 6, 2009, the Company entered into an Exclusive License Agreement with Ferring, under which the Company licensed certain of its patents and agreed to transfer know-how for its transdermal gel technology for certain pharmaceutical products. This agreement had no impact on the Company’s existing licenses, the transdermal clinical pipeline, or marketed products, including Gelnique 3%™, Nestragel™ (Nestorone®), and Elestrin®. Also on November 6, 2009, in tandem with the execution of the Exclusive License Agreement, the Company entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Ferring. Pursuant to the terms and conditions of the Purchase Agreement, Ferring purchased from the Company all of the assets, including equipment, fixtures, fittings and inventory, located at the Company’s research and development facility located in Allschwil, Switzerland (the “Facility”). Further pursuant to the terms and conditions of the Purchase Agreement, Ferring assumed the contractual obligations related to the Facility, including the real property lease for the Facility, and continued to employ the employees working at the Facility. The Company also entered into a Consultancy Services Agreement with Ferring for a period of 12 months, under which the Company provided services in connection with development of certain pharmaceutical products under the Exclusive License Agreement. Under these agreements the Company received upfront license fees, payments for assets and payments for services rendered under the consultancy agreement. In addition, the Company will receive milestone payments as certain defined milestones are achieved. The agreement is effective until the last to expire patent applicable under the agreement.

	Although there were three separate agreements with Ferring, they were evaluated as a single arrangement for purposes of applying the applicable accounting standard. Payments received under the Exclusive License Agreement were recognized over the 12 month period of the Consultancy Services Agreement, as this is the period of time the Company was involved in development. Payments received in connection with milestones will be recognized when the milestone payment is received. The amount received from Ferring for the assets sold resulted in a gain, which was recorded in other income.

	The Company entered into a License Agreement, dated January 22, 2003, with Ferring, under which the Company licensed certain of its intellectual property and extended the territories available to Ferring for use of certain of the Company’s reusable needle-free injector devices. Specifically, the Company granted to Ferring an exclusive, perpetual, irrevocable, royalty-bearing license, within a prescribed manufacturing territory, to manufacture certain of the Company’s reusable needle-free injector devices for the field of human growth hormone. The Company granted to Ferring similar non-exclusive rights outside of the prescribed manufacturing territory.

	As consideration for the license grants, Ferring paid the Company an upfront payment upon execution of the License Agreement, and paid an additional milestone in 2003. Ferring also pays the Company royalties for each device manufactured by or on behalf of Ferring, including devices manufactured by the Company. These royalty obligations expire, on a country-by-country basis, when the respective patents for the products expire, despite the fact that the License Agreement does not itself expire until the last of such patents expires. The license fees have been deferred and are being recognized in income over the period from 2003 through expiration of the patents in 2016.

	In March 2007, the Company amended the agreement increasing the royalty rate and device pricing, included a next generation device and provided for payment principally in U.S. dollars rather than Euros.

	In the fourth quarter of 2014, Ferring purchased the U.S. rights to Tev-Tropin from Teva. Tev-Tropin 10 mg is pending FDA approval.

	Actavis License and Commercialization Agreement

	In July 2011, the Company entered into an exclusive licensing agreement with Actavis to commercialize, in the U.S. and Canada, the Company’s topical oxybutynin gel 3% product, which was subsequently approved by the FDA in December 2011.

	Under this agreement the Company received payments for certain manufacturing start-up activities and delivery of launch quantities, and has received and is entitled to receive future royalties on both the Company’s oxybutynin gel 3% product and Actavis’ oxybutynin gel product Gelnique® 10%, and will potentially receive sales based milestone payments. The milestone payment based on the achievement of regulatory approval was subject to reimbursement to Actavis if launch quantities were not delivered within a certain defined time period. Actavis assumed all responsibility for manufacture and supply of the product in 2013. The term of the agreement ends on the later of April 2024 or the expiration date of the last to expire patent.



	Arrangement consideration has been allocated to the separate units of accounting based on the relative selling prices. Selling prices are determined using vendor specific objective evidence (“VSOE”), when available, third-party evidence (“TPE”), when available, or an estimate of selling price when neither of the first two options is available for a given unit of accounting. Selling prices in this arrangement were determined using estimated selling prices because VSOE and TPE were not available. The primary factors considered in determining selling price estimates in this arrangement were estimated costs, reasonable margin estimates and historical experience.

	The Company determined that the license and development activities, which include the manufacturing start-up activities, do not have value to the customer on a stand-alone basis as proprietary knowledge about the product and technology is required to complete the development activities. As a result, these deliverables do not qualify for treatment as separate units of accounting. Accordingly, the license and development activities have been accounted for as a single unit of accounting and arrangement consideration allocated to these deliverables was recognized as revenue over the development period, which ended upon manufacture of launch quantities. The sales based milestone payments will be recognized as revenue when earned, revenue for launch quantities was recognized when product was delivered to Actavis and royalties will be recognized as revenue when earned. The Company received a milestone payment from Actavis in December 2011 upon FDA approval, which was recorded as deferred revenue. This milestone payment was recognized as revenue in March of 2012, as launch quantities were delivered within the defined time period and the potential reimbursement liability was eliminated.

	Pfizer License Agreement

	In December 2011, the Company announced that it licensed to Pfizer, Inc.’s Consumer Healthcare Business Unit one of its drug delivery technologies to develop an undisclosed product on an exclusive basis for North America. Pfizer will assume full cost and responsibility for all clinical development, manufacturing, and commercialization of the product in the licensed territory, which also includes certain non-exclusive territories outside of North America. Antares received an upfront payment, and will receive development milestones and sales based milestones, as well as royalties on net sales for three years post launch in the U.S. Because the Company has no development responsibilities, the upfront and each milestone payment will be recognized as revenue when received. Royalties will be recognized as revenue when earned.

	Daewoong Development and License Agreement

	In January 2012, the Company entered into a licensing agreement with Daewoong Pharmaceuticals under which Daewoong will commercialize the Company’s oxybutynin gel 3% product in South Korea, once approved. This agreement was terminated in 2014.

	ANI License Agreement (formerly BioSante)

In June 2000, the Company entered into an exclusive agreement to license four applications of its drug-delivery technology to ANI Pharmaceuticals, formerly BioSante Pharmaceuticals (“ANI”), in the U.S., Canada, China, Australia, New Zealand, South Africa, Israel, Mexico, Malaysia and Indonesia (collectively, the “ANI Territories”). ANI will use the licensed technology for the development of hormone replacement therapy products. At the signing of the contract, ANI made an upfront payment to the Company, a portion of which, per the terms of the contract, was used to partially offset a later payment made to the Company as a result of an upfront payment received by ANI under a sublicense agreement. The initial upfront payment received by the Company was for the delivery of intellectual property to ANI. The term of the agreement ends on the later of the tenth anniversary of the first commercial sale of a product or the expiration date of the last to expire patent.

The Company will receive payments upon the achievement of certain milestones and will receive from ANI a royalty from the sale of licensed products. The Company will also receive a portion of any sublicense fees received by ANI.

In December 2009, ANI entered into a license agreement with Azur Pharma International II Limited (“Azur”), for Elestrin®. ANI has received payments from Azur which triggered sublicense payments to the Company. Because final regulatory approval for this product was obtained by ANI and Antares had no further obligations in connection with this product, the sublicense payments were recognized as revenue when received. Elestrin® is being marketed in the U.S. by Meda Pharma, who acquired the women’s health business from Jazz Pharmaceuticals (“Jazz”), who had previously acquired Azur. The Company has received royalties on sales of Elestrin®, which have been recognized as revenue when received.

Segment_Information_and_Signif

Segment Information and Significant Customers	12 Months Ended
Segment Information and Significant Customers	Dec. 31, 2014
Segment Reporting [Abstract]
Segment Information and Significant Customers	9	Segment Information and Significant Customers

	The Company has one operating segment, drug delivery, which includes the development of injection devices and injection based pharmaceutical products as well as transdermal gel products.

	Revenues by customer location are summarized as follows:



			For the Years Ended December 31,
			2014		2013		2012
	United States of America		$	21,409,371	$	16,479,855	$	16,964,635
	Europe			4,761,684		3,901,422		4,936,981
	Other			330,610		237,223		673,962

			$	26,501,665	$	20,618,500	$	22,575,578


	Revenues by product type:



			For the Years Ended December 31,
			2014		2013		2012
	Injection devices and supplies		$	25,245,200	$	18,156,217	$	12,642,537
	Transdermal gel products			1,256,465		2,462,283		9,933,041

			$	26,501,665	$	20,618,500	$	22,575,578


	The following summarizes significant customers comprising 10% or more of total revenue for the years ended December 31:



			2014		2013		2012
	Teva		$	8,682,384	$	13,559,541	$	7,495,978
	Ferring			4,760,084		3,827,098		4,933,369
	McKesson (1)			3,460,000		—		—
	LEO Pharma			3,428,571		571,428		—
	Actavis			449,862		1,489,942		6,770,635


	-1	Represents estimated revenue based on OTREXUP™ shipments, a portion of which has not been recognized as revenue but is recorded in deferred revenue at December 31, 2014 as discussed in Note 2 to the Consolidated Financial Statements.

	The following summarizes significant customers comprising 10% or more of outstanding accounts receivable as of December 31:



			2014		2013
	Teva		$	1,455,284	$	436,632
	Ferring			651,897		562,576
	Mckesson			797,763		—
	AmerisourceBergen			448,483		—

Legal_Proceedings

Legal Proceedings	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings	10	Legal Proceedings
	In the first quarter of 2014, Medac Pharma, Inc. (“Medac Pharma”) announced that it submitted a New Drug Application (“NDA”) to the FDA for an auto-pen containing methotrexate. On February 28, 2014, Antares filed a complaint against Medac Pharma and Medac GmbH, the parent company of Medac Pharma, (“Medac GmbH”, together with Medac Pharma, “Medac”) in the United States District Court for the District of Delaware, alleging infringement four of the Company’s patents. On March 14, 2014, Antares filed a motion for preliminary injunction seeking to enjoin Medac from selling its methotrexate auto-pen product if and when such product is approved for sale in the United States, pending the final resolution of the litigation. Two of Antares’ asserted patents were at issue in the preliminary injunction. On July 10, 2014, the District Court denied Antares’ motion for preliminary injunction. Antares has filed an appeal of the denial of the motion for preliminary injunction with the U.S. Court of Appeals for the Federal Circuit appealing the decision as to only one patent (RE44,846, the “’846 patent”). The ‘846 patent has 37 claims, and four were the subject of the appeal. On November 17, 2014, the Court of Appeals ruled that the District Court properly denied Antares’ motion for preliminary injunction because Antares cannot show likelihood of success on the merits, stating that four claims of the one patent on appeal are invalid for failure to satisfy the original patent requirement of 35 U.S.C. § 251. On December 17, 2014, Antares filed a petition seeking a rehearing by the Court of Appeals, and on February 23, 2015, the Court of Appeals denied the petition for rehearing. During the year ended December 31, 2014, a total of approximately $1,700,000 in legal costs in connection with this suit has been capitalized. However, there is no assurance of success with any patent litigation, and it could be costly and time consuming and depending on the ultimate outcome of the litigation may have an adverse effect on results of operations and OTREXUP™ market penetration. If the Company determines that the likelihood of a successful outcome of the entire action changes and becomes less than probable, the capitalized costs would be charged to expense in the period in which the change is determined.
	On March 7, 2014, Medac filed suit against Antares, LEO Pharma and its parent company, LEO Pharma A/S (LEO Pharma together with LEO Pharma A/S, the “LEO Entities”) in the United States District Court for the District of New Jersey, alleging that Antares and the LEO Entities infringe Medac Pharma’s U.S. Patent 8,664,231 (the “231 patent”) that was issued by the U.S. Patent and Trademark Office on March 4, 2014. The complaint states that the 231 patent relates to a concentration of more than 30mg/mL. Medac alleges that OTREXUP™ infringes the 231 patent and demands that Antares and the LEO Entities be enjoined from making, using, selling, importing or offering OTREXUP™ and pay unspecified amounts of compensatory damages, treble damages and attorneys’ fees. On November 18, 2014, Medac filed a motion for preliminary injunction seeking to enjoin Antares and the LEO Entities from selling OTREXUP in the United States, pending the final resolution of the litigation. The Company intends to defend itself vigorously. Under the terms of the promotion and license agreement between the Company and the LEO Entities, the Company agreed to indemnify the LEO Entities from claims that OTREXUP™ infringes the intellectual property rights of any third party. On July 1, 2014, Antares filed a petition with the Patent Trial and Appeal Board (the “PTAB”) of the U.S. Patent and Trademark Office seeking an inter partes review of Medac’s ’231 patent challenging the validity of the’231 patent. On January 6, 2015, the PTAB issued an order instituting an inter partes review of all claims of the ’231 patent. Legal costs in connection with these proceedings are expensed as incurred.

Quarterly_Financial_Data_unaud

Quarterly Financial Data (unaudited)	12 Months Ended
Quarterly Financial Data (unaudited)	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Data (unaudited)	11	Quarterly Financial Data (unaudited)

			First			Second			Third			Fourth
	2014:00:00
	Total revenues		$	5,202,195		$	6,326,785		$	6,570,581		$	8,402,104
	Gross profit			4,025,450			4,196,705			4,063,215			2,979,600
	Net loss (1)			(8,794,605	)		(9,097,725	)		(7,186,441	)		(10,072,944	)
	Net loss per common share (2)			(0.07	)		(0.07	)		(0.05	)		(0.08	)
	Weighted average shares			129,656,257			130,051,896			130,771,380			131,694,429

	2013:00:00
	Total revenues (3)		$	4,528,222		$	5,837,544		$	5,507,824		$	4,744,910
	Gross profit (3)			2,501,079			2,356,862			2,503,222			4,060,107
	Net loss			(3,408,448	)		(5,103,256	)		(6,359,957	)		(5,635,115	)
	Net loss per common share (2)			(0.03	)		(0.04	)		(0.05	)		(0.04	)
	Weighted average shares			126,106,713			126,462,677			127,162,064			127,835,641

	-1	In December 2014, the Company received an invoice from the FDA in the amount of $970,840 for user fees related to OTREXUP™ for the twelve month period ended September 30, 2014 for which approximately $243,000 should have been recorded in the fourth quarter of 2013 and in the first, second and third quarters of 2014. The Company had not previously recorded the expense associated with this invoice and the full amount was recorded in research and development expenses in the fourth quarter of 2014 in the table above. The Company has evaluated this out of period adjustment and has determined that it is not material to the Company’s financial position or results of operations for any of the quarterly periods in 2013 or 2014.
	-2	Net loss per common share is computed based upon the weighted average number of shares outstanding during each period. Basic and diluted loss per share amounts are identical as the effect of potential common shares is anti-dilutive.
	-3	Total revenues in the fourth quarter of 2013 included over $1.1 million more licensing and royalty revenue than in each of the prior three quarters, resulting in a higher gross profit as there were no associated costs with these revenues. Also impacting gross profit in the fourth quarter was development revenue having a higher gross profit than development revenue in prior quarters.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Basis of Presentation

Use of Estimates

Foreign Currency Translation

Cash Equivalents

The Company considers highly liquid debt instruments with original maturities of 90 days or less to be cash equivalents.

Allowance for Doubtful Accounts

Inventories

Equipment, Molds, Furniture, and Fixtures

Goodwill

The Company’s evaluation of goodwill resulted in no impairment losses in 2014, 2013 and 2012.

Patent Rights

Impairment of Long-Lived Assets and Long-Lived Assets to Be Disposed Of

Fair Value of Financial Instruments

Cash and cash equivalents are stated at cost, which approximates fair value.

Revenue Recognition

Otrexup Revenue Recognition

Product Sales Allowances

Other Revenue Recognition

Revenue arrangements with multiple deliverables are divided into separate units of accounting if certain criteria are met, including whether the deliverable has stand-alone value to the customer, the customer has a general right of return relative to the delivered item and delivery or performance of the undelivered item is probable and substantially within the vendor’s control. Arrangement consideration is allocated at the inception of the arrangement to all deliverables on the basis of their relative selling price. The selling price for each deliverable is determined using: (i) vendor-specific objective evidence of selling price ("VSOE"), if it exists, (ii) third-party evidence of selling price ("TPE") if VSOE does not exist, and (iii) the Company’s best estimate of the selling price if neither VSOE nor TPE exists. For transactions entered into prior to January 1, 2011, revenue is recognized for each deliverable based upon the applicable revenue recognition criteria discussed above and upon acceptance of goods or performance of service. Effective January 1, 2011, for new or significantly modified transactions, the Company allocates revenue consideration, excluding contingent consideration, based on the relative selling prices of the separate units of accounting contained within an arrangement containing multiple deliverables.

Shipping and Handling Costs

The Company records shipping and handling costs in cost of product sales.

Share-Based Compensation

The Company utilizes share based compensation in the form of stock options, restricted stock units ("RSUs") and performance-based restricted stock units ("PSUs"). The Company records compensation expense associated with share based awards granted to employees at the fair value of the award on the date of grant. The Company uses the Black-Scholes option valuation model to determine the fair value of stock options. The fair values of RSU and PSU grants containing service or performance conditions are based on the market value of the Company’s Common Stock on the date of grant. The fair value of PSUs containing market condition are estimated using a Monte Carlo simulation. Pre-vesting forfeitures are estimated in the determination of total stock-based compensation cost based on Company experience. The value of the portion of the award that is ultimately expected to vest is expensed ratably over the requisite service period as compensation expense in the consolidated statement of operations. The determination of fair value of share-based payment awards on the grant date requires significant judgment. Assumptions concerning the Company’s stock price volatility and projected employee exercise behavior over the contractual life of the award can significantly impact the estimated fair value of an award. Given the Company’s limited history, such assumptions may not be reflective of the patterns that will ultimately be experienced.

Product Warranty

Balance at

Provisions

Claims

Balance at

Beginning of

End of

Year

2014

100,000

5,100

(5,100

)

100,000

2013

100,000

50,819

(50,819

)

100,000

2012

100,000

72,893

(72,893

)

100,000

Research and Development

Income Taxes

deferred tax assets, and as of December 31, 2013, a valuation allowance was established to offset all of the U.S. net deferred tax assets. For the year ended December 31, 2013, the Company determined it was more likely than not that a portion of the deferred tax assets would be realized and recorded an income tax benefit of $300,000 after releasing $300,000 of the valuation allowance related to the Switzerland deferred tax assets. For the year ended December 31, 2014, the Company recorded income tax expense related to the Swiss operations of $25,000, reducing deferred tax assets to $275,000 at December 31, 2014.

Net Loss Per Share

2014

2013

2012

Stock options and warrants

7,245,485

8,242,992

10,830,530

Recent Accounting Pronouncements

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
Summary of Significant Accounting Policies (Tables)	Dec. 31, 2014
Accounting Policies [Abstract]
Summary of Warranty Liability Activity	Warranty liability activity is as follows:


		Balance at		Provisions		Claims			Balance at
		Beginning of							End of
		Year							Year
	2014	$	100,000	$	5,100	$	(5,100	)	$	100,000
	2013	$	100,000	$	50,819	$	(50,819	)	$	100,000
	2012	$	100,000	$	72,893	$	(72,893	)	$	100,000
Summary of Potentially Dilutive Securities Excluded from Dilutive Loss Per Share	Potentially dilutive securities at December 31, 2014, 2013 and 2012, excluded from dilutive loss per share as their effect is anti-dilutive, are as follows:


		2014		2013		2012
	Stock options and warrants		7,245,485		8,242,992		10,830,530

Composition_of_Certain_Financi1

Composition of Certain Financial Statement Captions (Tables)	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of Composition of Certain Financial Statement Captions

		December 31,			December 31,
		2014			2013
	Inventories:
	Raw material	$	461,396		$	1,056,054
	Work in process		3,896,837			3,034,321
	Finished goods		1,501,691			2,370,676

		$	5,859,924		$	6,461,051


	Equipment, molds, furniture and fixtures:
	Furniture, fixtures and office equipment	$	1,551,100		$	1,501,612
	Production molds and equipment		8,322,631			7,389,062
	Molds and tooling in process		3,836,650			424,521
	Less accumulated depreciation		(2,881,640	)		(2,362,944	)

		$	10,828,741		$	6,952,251


	Patent rights:
	Patent rights	$	4,468,166		$	2,635,706
	Less accumulated amortization		(1,583,142	)		(1,290,529	)

		$	2,885,024		$	1,345,177


	Accrued expenses and other liabilities:
	Accrued employee compensation and benefits	$	1,559,255		$	2,348,456
	Liabilities related to OTREXUP™ commercialization and development expenses		1,922,422			1,946,869
	OTREXUP™ reserves for discounts, rebates, allowances		230,768			—
	Other liabilities		1,923,114			1,157,750

		$	5,635,559		$	5,453,075

Leases_Tables

Leases (Tables)	12 Months Ended
Leases (Tables)	Dec. 31, 2014
Leases [Abstract]
Summary of Future Minimum Lease Payments	Future minimum lease payments under operating leases with remaining terms in excess of one year as of December 31, 2014 were as follows:


		Amount
	2015	$	594,806
	2016		599,539
	2017		611,067
	2018		622,716
	2019		565,955
	Thereafter		530,993

	Total future minimum lease payments	$	3,525,076

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax Domestic and Foreign	Income (loss) before income taxes was derived from the following jurisdictions:



		2014			2013			2012
	U.S.	$	(35,359,378	)	$	(21,568,727	)	$	(16,477,710	)
	Switzerland		232,663			761,951			5,050,260

		$	(35,126,715	)	$	(20,806,776	)	$	(11,427,450	)



Summary of Effective Tax Rates Differ from Statutory Income Tax Rates	Effective tax rates differ from statutory income tax rates in the years ended December 31, 2014, 2013 and 2012 as follows:



		2014			2013			2012
	Statutory income tax rate		(34.0	)%		(34.0	)%		(34.0	)%
	State income taxes		(3.7	)		(1.0	)		(3.6	)
	Valuation allowance increase (decrease)		37.8			28.8			29.8
	Effect of foreign operations		(0.2	)		(0.7	)		(8.5	)
	Change in unused net operating loss and credit carryforwards		(0.2	)		(1.0	)		14
	Nondeductible items		0.4			6.5			0.6
	Other		—			—			1.7

			0.1	%		(1.4	)%		0	%

Summary of Deferred Tax Assets	Deferred tax assets (liabilities) as of December 31, 2014 and 2013 consist of the following:



		2014			2013
	Gross deferred tax assets:
	Net operating loss carryforward – U.S.	$	40,428,000		$	28,832,000
	Net operating loss carryforward – Switzerland		3,128,000			4,556,000
	Research and development tax credit carryforward		3,617,000			2,589,000
	Deferred revenue		1,292,000			320,000
	Stock-based compensation		1,677,000			1,581,000
	Inventory reserve		1,356,000			18,000
	Compensation accruals		425,000			38,000
	Other		41,000			37,000

			51,964,000			37,971,000
	Gross deferred tax liabilities - depreciation and amortization		(648,000	)		(105,000	)
	Less valuation allowance		(51,041,000	)		(37,566,000	)

	Net deferred tax asset	$	275,000		$	300,000

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	12 Months Ended
Stockholders' Equity (Tables)	Dec. 31, 2014
Summary of Stock Option Activity	A summary of stock option activity under the Plan as of December 31, 2014 and the changes during the three years then ended is as follows:


		Number of			Weighted			Weighted			Aggregate
		Shares			Average			Average			Intrinsic Value
					Exercise Price			Remaining			($)
					($)			Contractual
								Term (Years)
	Outstanding at December 31, 2011		7,785,672			1.21
	Granted/Issued		1,334,731			3.18
	Exercised		(1,164,636	)		1.2						2,620,360
	Cancelled/Forfeited		(141,206	)		4.06

	Outstanding at December 31, 2012		7,814,561			1.49
	Granted/Issued		1,129,380			3.99
	Exercised		(981,385	)		0.72						3,319,471
	Cancelled/Forfeited		(264,664	)		3.48

	Outstanding at December 31, 2013		7,697,892			1.89
	Granted/Issued		2,596,201			2.89
	Exercised		(2,124,123	)		1.21						3,585,453
	Cancelled/Forfeited		(924,485	)		3.41

	Outstanding at December 31, 2014		7,245,485			2.25			6.7			4,640,730

	Exercisable at December 31, 2014		4,876,651			1.87			5.4			4,461,950

Assumptions Used in Fair Value Measurement of Options Granted
		December 31,
		2014			2013			2012
	Risk-free interest rate		1.6	%		0.9	%		0.7	%
	Annualized volatility		60.7	%		62	%		61	%
	Weighted average expected life, in years		6			6			5
	Expected dividend yield		0	%		0	%		0	%
Schedule of Performance Stock Unit Awards and Restricted Stock Granted Under Long Term Incentive Program	The performance stock unit awards and restricted stock granted under the long term incentive program are summarized in the following table:


		Performance Stock Units						Restricted Stock
		Number of			Weighted			Number of			Weighted
		Shares			Average Fair			Shares			Average Fair
					Value ($)						Value ($)
	Outstanding at December 31, 2011		182,000			1.66			—			—
	Granted		137,715			4.26			—			—
	Vested		—			—			—			—
	Forfeited/Expired		—			—			—			—

	Outstanding at December 31, 2012		319,715			2.78			—			—
	Granted		185,185			3.96			185,185			3.96
	Vested		—			—			—			—
	Forfeited/Expired		(98,237	)		3.32			(29,461	)		3.96

	Outstanding at December 31, 2013		406,663			3.19			155,724			3.96
	Granted		651,980			3.02			325,991			3.02
	Vested		(87,519	)		2.03			(51,907	)		3.96
	Forfeited/Expired		(507,582	)		3.26			(198,684	)		3.45

	Outstanding at December 31, 2014		463,542			3.08			231,124			3.07


Summary of Warrant Activity	Warrant activity is summarized as follows:


		Number of			Weighted
		Shares			Average Price ($)
	Outstanding at December 31, 2011		10,075,284			1.66
	Exercised		(7,056,075	)		1.53
	Cancelled		(3,240	)		2

	Outstanding at December 31, 2012		3,015,969			1.98
	Exercised		(1,470,869	)		1.11
	Cancelled		(1,000,000	)		3.78

	Outstanding at December 31, 2013		545,100			1
	Exercised		(545,100	)		1

	Outstanding at December 31, 2014		—


Performance Stock Units [Member]
Assumptions Used in Fair Value Measurement of Options Granted	The fair value of the TSR PSUs granted in 2014 was determined using a Monte Carlo simulation and utilized the following inputs and assumptions:


	Closing stock price on grant date	$	3.09
	Performance period starting price	$	4.08
	Term of award (in years)		2.59
	Volatility		50.87	%
	Risk-free interest rate		0.61	%
	Expected dividend yield		0	%
	Fair value per TSR PSU	$	2.64

Segment_Information_and_Signif1

Segment Information and Significant Customers (Tables)	12 Months Ended
Segment Information and Significant Customers (Tables)	Dec. 31, 2014
Segment Reporting [Abstract]
Summary of Revenues by Customer Location	Revenues by customer location are summarized as follows:


		For the Years Ended December 31,
		2014		2013		2012
	United States of America	$	21,409,371	$	16,479,855	$	16,964,635
	Europe		4,761,684		3,901,422		4,936,981
	Other		330,610		237,223		673,962

		$	26,501,665	$	20,618,500	$	22,575,578

Revenues By Product Type	Revenues by product type:


		For the Years Ended December 31,
		2014		2013		2012
	Injection devices and supplies	$	25,245,200	$	18,156,217	$	12,642,537
	Transdermal gel products		1,256,465		2,462,283		9,933,041

		$	26,501,665	$	20,618,500	$	22,575,578

Summary of Significant Customers Comprising 10% or More of Total Revenue	The following summarizes significant customers comprising 10% or more of total revenue for the years ended December 31:



		2014		2013		2012
	Teva	$	8,682,384	$	13,559,541	$	7,495,978
	Ferring		4,760,084		3,827,098		4,933,369
	McKesson (1)		3,460,000		—		—
	LEO Pharma		3,428,571		571,428		—
	Actavis		449,862		1,489,942		6,770,635
Summary of Significant Customers Comprising 10% or More of Outstanding Accounts Receivable	The following summarizes significant customers comprising 10% or more of outstanding accounts receivable as of December 31:


		2014		2013
	Teva	$	1,455,284	$	436,632
	Ferring		651,897		562,576
	Mckesson		797,763		—
	AmerisourceBergen		448,483		—

Quarterly_Financial_Data_unaud1

Quarterly Financial Data (unaudited) (Tables)	12 Months Ended
Quarterly Financial Data (unaudited) (Tables)	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Data	First				Second			Third			Fourth
	2014:00:00
	Total revenues		$	5,202,195		$	6,326,785		$	6,570,581		$	8,402,104
	Gross profit			4,025,450			4,196,705			4,063,215			2,979,600
	Net loss (1)			(8,794,605	)		(9,097,725	)		(7,186,441	)		(10,072,944	)
	Net loss per common share (2)			(0.07	)		(0.07	)		(0.05	)		(0.08	)
	Weighted average shares			129,656,257			130,051,896			130,771,380			131,694,429

	2013:00:00
	Total revenues (3)		$	4,528,222		$	5,837,544		$	5,507,824		$	4,744,910
	Gross profit (3)			2,501,079			2,356,862			2,503,222			4,060,107
	Net loss			(3,408,448	)		(5,103,256	)		(6,359,957	)		(5,635,115	)
	Net loss per common share (2)			(0.03	)		(0.04	)		(0.05	)		(0.04	)
	Weighted average shares			126,106,713			126,462,677			127,162,064			127,835,641

	-1	In December 2014, the Company received an invoice from the FDA in the amount of $970,840 for user fees related to OTREXUP™ for the twelve month period ended September 30, 2014 for which approximately $243,000 should have been recorded in the fourth quarter of 2013 and in the first, second and third quarters of 2014. The Company had not previously recorded the expense associated with this invoice and the full amount was recorded in research and development expenses in the fourth quarter of 2014 in the table above. The Company has evaluated this out of period adjustment and has determined that it is not material to the Company’s financial position or results of operations for any of the quarterly periods in 2013 or 2014.
	-2	Net loss per common share is computed based upon the weighted average number of shares outstanding during each period. Basic and diluted loss per share amounts are identical as the effect of potential common shares is anti-dilutive.
	-3	Total revenues in the fourth quarter of 2013 included over $1.1 million more licensing and royalty revenue than in each of the prior three quarters, resulting in a higher gross profit as there were no associated costs with these revenues. Also impacting gross profit in the fourth quarter was development revenue having a higher gross profit than development revenue in prior quarters.

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	12 Months Ended			3 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013
	Subsidiaries	Dec. 31, 2013	Dec. 31, 2012	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013
Summary Of Significant Accounting Policies [Line Items]
Wholly-owned subsidiaries of Antares Pharma	3
Accounts receivable balance due	98.00%
Bad debt expense	$37,000	$0	$0
Allowance for doubtful accounts balance	10,000	10,000					10,000
Inventory reserve	3,600,000	50,000					50,000
Depreciation expense	880,400	359,471	145,775
Goodwill	1,095,355	1,095,355					1,095,355
Market capitalization of the Company	339,000,000
Goodwill impairment loss	0	0	0
Capitalized legal patent cost	1,800,000	100,000					100,000
Amortization expense	343,817	133,788	85,253
Impairment charges	0		0
Patent rights	4,468,166	2,635,706					2,635,706
Accumulated amortization of patents	1,583,142	1,290,529					1,290,529
Aggregate patent amortization expense, 2015	523,000
Aggregate patent amortization expense, 2016	539,000
Aggregate patent amortization expense, 2017	539,000
Aggregate patent amortization expense, 2018	539,000
Aggregate patent amortization expense, 2019	314,000
Patent write off		65,022
Short term investments, fair value	6,005,040	24,021,522					24,021,522
Short term investments, carrying value	6,002,438	24,014,305					24,014,305
Long-term investments, fair value		6,007,851					6,007,851
Long-term investments, carrying value		6,008,169					6,008,169
Long-term investments maturity	2 years
Deferred revenue balance	10,807,596
Method used for fair value assumption	Black-Scholes option valuation model
Warranty period of device	24 months
Research and development expense	18,638,016	15,263,371	14,921,552
Valuation allowance for deferred tax assets	51,041,000	37,566,000					37,566,000
Income tax provision (benefit)	25,000	-300,000
Deferred tax assets	275,000	300,000					300,000
United States of America [Member]
Summary Of Significant Accounting Policies [Line Items]
Product revenue	7,309,603
Deferred revenue balance	1,061,947
Cash discount to incentive for prompt payment	2.00%
Switzerland [Member]
Summary Of Significant Accounting Policies [Line Items]
Valuation allowance for deferred tax assets		300,000					300,000
Income tax provision (benefit)	25,000
Deferred tax assets	275,000
U.S. Deferred Tax Assets [Member]
Summary Of Significant Accounting Policies [Line Items]
Income tax provision (benefit)		-300,000
Otrexuptm [Member]
Summary Of Significant Accounting Policies [Line Items]
Research and development expense	$970,840	$243,000		$243,000	$243,000	$243,000	$243,000
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Debt instruments maturity	90 days
Estimated useful lives	10 years
Capitalized cost being amortized over periods	15 years
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives	3 years
Capitalized cost being amortized over periods	5 years

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Summary of Warranty Liability Activity (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Movement in Standard and Extended Product Warranty, Increase (Decrease) [Roll Forward]
Balance at Beginning of Year	$100,000	$100,000	$100,000
Provisions	5,100	50,819	72,893
Claims	-5,100	-50,819	-72,893
Balance at End of Year	$100,000	$100,000	$100,000

Summary_of_Significant_Account5

Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities Excluded from Dilutive Loss Per Share (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Equity [Abstract]
Stock options and warrants	7,245,485	8,242,992	10,830,530

Composition_of_Certain_Financi2

Composition of Certain Financial Statement Captions - Summary of Composition of Certain Financial Statement Captions (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Inventories:
Raw material	$461,396	$1,056,054
Work in process	3,896,837	3,034,321
Finished goods	1,501,691	2,370,676
Inventory, Total	5,859,924	6,461,051
Equipment, molds, furniture and fixtures:
Furniture, fixtures and office equipment	1,551,100	1,501,612
Production molds and equipment	8,322,631	7,389,062
Molds and tooling in process	3,836,650	424,521
Less accumulated depreciation	-2,881,640	-2,362,944
Equipment, molds, furniture and fixtures, Total	10,828,741	6,952,251
Patent rights:
Patent rights	4,468,166	2,635,706
Less accumulated amortization	-1,583,142	-1,290,529
Patent rights, Total	2,885,024	1,345,177
Accrued expenses and other liabilities:
Accrued employee compensation and benefits	1,559,255	2,348,456
Other liabilities	1,923,114	1,157,750
Accrued expenses and other liabilities	5,635,559	5,453,075
Otrexuptm [Member]
Accrued expenses and other liabilities:
Liabilities related to OTREXUPb" commercialization and development expenses	1,922,422	1,946,869
OTREXUPb"reserves for discounts, rebates, allowances	$230,768

Leases_Additional_Information_

Leases - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
	Dec. 31, 2014	sqft	Dec. 31, 2012
Leases [Abstract]
Rent expense	$611,818	$453,142	$325,971
Research and development office space in a new Plymouth location, square feet		18,000

Leases_Summary_of_Future_Minim

Leases - Summary of Future Minimum Lease Payments (Detail) (USD $)	Dec. 31, 2014
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2015	$594,806
2016	599,539
2017	611,067
2018	622,716
2019	565,955
Thereafter	530,993
Total future minimum lease payments	$3,525,076

Income_Taxes_Additional_Inform

Income Taxes - Additional Informations (Detail) (USD $)	12 Months Ended
Income Taxes - Additional Informations (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Operating Loss Carryforwards [Line Items]
Period of incurred losses for both book and tax purposes	3 years
Valuation allowance for deferred tax assets	$51,041,000	$37,566,000
Increased and decreased total valuation allowance	13,475,000	5,076,000
Recognized tax expense	25,000	-300,000
Unrecognized tax benefits	0	0
Interest or penalties charged in relation to unrecognized tax benefits	0
Interest or penalties accrued in relation to unrecognized tax benefits	0
Total unrecognized tax benefits changing period	12 months
Switzerland [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards were used to fully offset book and tax income	200,000	500,000	5,500,000
Valuation allowance for deferred tax assets		300,000
Benefit of deferred tax assets	25,000
Taxable income from operations	200,000
Recognized tax expense	25,000
U.S Federal Tax [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carry forward	116,800,000
Expiring net operating loss carryforward amount	5,600,000
Research credit carryforward	3,600,000
Net operating loss carryforward expiration years, description	2018 through 2034
Foreign Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carry forward	23,200,000
Expiring net operating loss carryforward amount	$22,700,000
Net operating loss carryforward expiration years, description	2015 through 2018
Expiring period of net operating loss carryforward	3 years

Income_Taxes_Schedule_of_Incom

Income Taxes - Schedule of Income before Income Tax Domestic and Foreign (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest [Abstract]
Income (loss) before income taxes, US	($35,359,378)	($21,568,727)	($16,477,710)
Income (loss) before income taxes, Switzerland	232,663	761,951	5,050,260
Net loss before income taxes	($35,126,715)	($20,806,776)	($11,427,450)

Income_Taxes_Summary_of_Effect

Income Taxes - Summary of Effective Tax Rates Differ from Statutory Income Tax Rates (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Statutory income tax rate	-34.00%	-34.00%	-34.00%
State income taxes	-3.70%	-1.00%	-3.60%
Valuation allowance increase (decrease)	37.80%	28.80%	29.80%
Effect of foreign operations	-0.20%	-0.70%	-8.50%
Change in unused net operating loss and credit carryforwards	-0.20%	-1.00%	14.00%
Nondeductible items	0.40%	6.50%	0.60%
Other			1.70%
Effective income tax rate, Total	0.10%	-1.40%	0.00%

Income_Taxes_Summary_of_Deferr

Income Taxes - Summary of Deferred Tax Assets (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Gross deferred tax assets:
Net operating loss carryforward - U.S.	$40,428,000	$28,832,000
Net operating loss carryforward - Switzerland	3,128,000	4,556,000
Research and development tax credit carryforward	3,617,000	2,589,000
Deferred revenue	1,292,000	320,000
Stock-based compensation	1,677,000	1,581,000
Inventory reserve	1,356,000	18,000
Compensation accruals	425,000	38,000
Other	41,000	37,000
Deferred tax asset, Total	51,964,000	37,971,000
Gross deferred tax liabilities - depreciation and amortization	-648,000	-105,000
Less valuation allowance	-51,041,000	-37,566,000
Net deferred tax asset	$275,000	$300,000

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	1 Months Ended		12 Months Ended
	Nov. 30, 2012	Oct. 31, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from issuance of common stock, net					$53,328,188
Share-based compensation arrangement by share-based payment award, number of shares authorized			21,000,000
Maximum number of shares of stock granted to one participant			1,000,000
Minimum percentage of exercise price			100.00%
Shares available for grant under the plan			4,250,074
Number of Shares Granted			2,596,201	1,129,380	1,334,731
Shares withheld to meet employees' minimum statutory income tax obligation			38,768	30,153	11,165
Payments for the employees' minimum statutory income tax obligation			154,397	104,329	28,916
Long Term Incentive Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual term of options granted			10 years
Performance stock unit awards expenses			3,000
Performance stock unit awards expenses and probable achievement				259,000
Long Term Incentive Program [Member] \| Equity Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation award percentage			25.00%	33.00%
Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual term of options granted			10 years
Vesting period			3 years
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock, shares	1,759,868	12,500,000			14,259,868
Common stock price per shares	$4	$4
Proceeds from issuance of common stock, net		53,328,188
Common stock offering expenses		3,711,284
Proceeds from the issuance of stock options			2,564,987	692,348	792,203
Issuance of shares of common stock Options			2,124,123	981,385	965,597
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from warrant exercised			545,115	1,634,490	10,787,210
Issuance of shares of common stock Warrants			545,100	1,470,869	7,056,075
Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Recognized compensation cost related to shares of stock granted			356,000	679,500	560,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to nonvested outstanding stock awards			3,400,000
Weighted average period expected to be recognized			2 years 2 months 12 days
Recognized compensation cost related to shares of stock granted			2,060,000	1,364,000	1,164,000
Per share weighted average fair value of options granted			$1.64	$2.26	$1.64
Exercised stock option which did not generate cash					583,344
Issuance of shares of common stock from cashless option exercises			384,305
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based payment performance awards shares granted					35,000
Per share weighted average grant date fair value of stock units			$3.02	$3.96	$4.26
Performance Stock Units [Member] \| Long Term Incentive Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Recognized compensation cost related to shares of stock granted			66,280
Share based compensation award percentage			50.00%	33.00%
Per share weighted average grant date fair value of stock units			$2.64
Performance Stock Units [Member] \| Long Term Incentive Program [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation award percentage			0.00%
Performance Stock Units [Member] \| Long Term Incentive Program [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation award percentage			150.00%
Discretionary Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Recognized compensation cost related to shares of stock granted				8,722	301,017
Share based payment discretionary awards shares granted			150,000	0	60,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Per share weighted average grant date fair value of stock units			$3.02	$3.96
Restricted Stock [Member] \| Long Term Incentive Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			3 years
Recognized compensation cost related to shares of stock granted			$212,000	$125,000
Share based compensation award percentage			25.00%	33.00%
Restricted Stock [Member] \| Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares Granted			0

Stockholders_Equity_Summary_of

Stockholders' Equity - Summary of Stock Option Activity (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Stockholders' Equity Note [Abstract]
Number of Shares Outstanding, Beginning	7,697,892	7,814,561	7,785,672
Weighted Average Exercise Price Outstanding, Beginning Balance	$1.89	$1.49	$1.21
Number of Shares Granted/Issued	2,596,201	1,129,380	1,334,731
Number of Shares Exercised	-2,124,123	-981,385	-1,164,636
Number of Shares Cancelled/Forfeited	-924,485	-264,664	-141,206
Number of Shares Outstanding, Ending	7,245,485	7,697,892	7,814,561
Number of Shares Exercisable, Ending	4,876,651
Weighted Average Exercise Price Granted/Issued	$2.89	$3.99	$3.18
Weighted Average Exercise Price Exercised	$1.21	$0.72	$1.20
Weighted Average Exercise Price Cancelled/Forfeited	$3.41	$3.48	$4.06
Weighted Average Exercise Price Outstanding, Ending Balance	$2.25	$1.89	$1.49
Weighted Average Exercise Price Exercisable, Ending Balance	$1.87
Weighted Average Remaining Contractual Term Outstanding, Ending	6 years 8 months 12 days
Weighted Average Remaining Contractual Term Exercisable, Ending	5 years 4 months 24 days
Aggregate Intrinsic Value, Exercised	$3,585,453	$3,319,471	$2,620,360
Aggregate Intrinsic Value Outstanding, Ending	4,640,730
Aggregate Intrinsic Value Exercisable, Ending	$4,461,950

Stockholders_Equity_Assumption

Stockholders' Equity - Assumptions Used in Fair Value Measurement of Options Granted (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Stockholders' Equity Note [Abstract]
Risk-free interest rate	1.60%	0.90%	0.70%
Annualized volatility	60.70%	62.00%	61.00%
Weighted average expected life, in years	6 years	6 years	5 years
Expected dividend yield	0.00%	0.00%	0.00%

Stockholders_Equity_Fair_Value

Stockholders' Equity - Fair Value of PSUs Granted Determined Using Monte Carlo Simulation (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of award (in years)	6 years	6 years	5 years
Volatility	60.70%	62.00%	61.00%
Risk-free interest rate	1.60%	0.90%	0.70%
Expected dividend yield	0.00%	0.00%	0.00%
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Closing stock price on grant date	3.09
Performance period starting price	4.08
Term of award (in years)	2 years 7 months 2 days
Volatility	50.87%
Risk-free interest rate	0.61%
Expected dividend yield	0.00%
Fair value per TSR PSU	2.64

Stockholders_Equity_Schedule_o

Stockholders' Equity - Schedule of Performance Stock Unit Awards and Restricted Stock Granted Under Long Term Incentive Program (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning Balance	406,663	319,715	182,000
Number of Shares, Granted	651,980	185,185	137,715
Number of Shares, Vested	-87,519
Number of Shares, Forfeited/Expired	-507,582	-98,237
Number of Shares, Ending Balance	463,542	406,663	319,715
Weighted Average Fair Value, Beginning Balance	$3.19	$2.78	$1.66
Weighted Average Fair Value, Granted	$3.02	$3.96	$4.26
Weighted Average Fair Value, Vested	$2.03
Weighted Average Fair Value, Forfeited/Expired	$3.26	$3.32
Weighted Average Fair Value, Ending Balance	$3.08	$3.19	$2.78
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning Balance	155,724
Number of Shares, Granted	325,991	185,185
Number of Shares, Vested	-51,907
Number of Shares, Forfeited/Expired	-198,684	-29,461
Number of Shares, Ending Balance	231,124	155,724
Weighted Average Fair Value, Beginning Balance	$3.96
Weighted Average Fair Value, Granted	$3.02	$3.96
Weighted Average Fair Value, Vested	$3.96
Weighted Average Fair Value, Forfeited/Expired	$3.45	$3.96
Weighted Average Fair Value, Ending Balance	$3.07	$3.96

Stockholders_Equity_Summary_of1

Stockholders' Equity - Summary of Warrant Activity (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Stockholders' Equity Note [Abstract]
Warrants Number of Shares, Beginning balance	545,100	3,015,969	10,075,284
Warrants Number of Shares, Exercised	-545,100	-1,470,869	-7,056,075
Warrants Number of Shares, Cancelled		-1,000,000	-3,240
Warrants Number of Shares, Ending balance		545,100	3,015,969
Warrants Weighted Average Price, Beginning balance	$1	$1.98	$1.66
Warrants Weighted Average Price, Exercised	$1	$1.11	$1.53
Warrants Weighted Average Price, Cancelled		$3.78	$2
Warrants Weighted Average Price, Ending balance		$1	$1.98

Employee_401k_Savings_Plan_Add

Employee 401(k) Savings Plan - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Postemployment Benefits [Abstract]
Maximum employee plan contribution percentage of compensation	50.00%
Company plan contributions	$373,000	$230,000	$173,000

License_Agreements_Additional_

License Agreements - Additional Information (Detail) (USD $)	1 Months Ended	12 Months Ended		0 Months Ended	1 Months Ended			12 Months Ended	1 Months Ended
	Nov. 30, 2013	Dec. 31, 2014	Dec. 31, 2013	31-May-13	Jan. 31, 2011	Dec. 31, 2007	Jul. 31, 2006	Dec. 31, 2012	Jun. 30, 2000
	Nov. 30, 2013	Dec. 31, 2014	Dec. 31, 2013	31-May-13	Product	Product	Jul. 31, 2006	Dec. 31, 2012	Jun. 30, 2000
Deferred Revenue Arrangement [Line Items]
Recognition of revenue previously deferred		$3,429,000	$571,000
Deferred revenue recorded		6,000,000
Non refundable upfront payment	5,000,000
Revenue recognition period of deliverables		35 months
Performance Obligations [Member]
Deferred Revenue Arrangement [Line Items]
Milestone payment received	5,000,000
Sales Revenue, Net [Member]
Deferred Revenue Arrangement [Line Items]
Milestone payment receivable	10,000,000
Development and License Agreement [Member]
Deferred Revenue Arrangement [Line Items]
Recognition of revenue previously deferred		560,000
Deferred revenue recorded		115,000
Teva License Supply and Distribution Agreement [Member]
Deferred Revenue Arrangement [Line Items]
Term of the agreement		7 years
Period for automatic renewals		1 year		1 year		2 years
Number of undisclosed patient-administered pharmaceutical products					2	2
Device or product filed period						12 months	12 months
Period of terminated by either party				6 months
Teva License Supply and Distribution Agreement [Member] \| Licensing Agreements [Member]
Deferred Revenue Arrangement [Line Items]
Recognition of revenue previously deferred								$62,225
Teva License Supply and Distribution Agreement [Member] \| Parent Company [Member]
Deferred Revenue Arrangement [Line Items]
Percentage of profit distribution		50.00%
Teva License Supply and Distribution Agreement [Member] \| Teva [Member]
Deferred Revenue Arrangement [Line Items]
Percentage of profit distribution		50.00%
Ferring Agreements [Member]
Deferred Revenue Arrangement [Line Items]
Consultancy Services Agreement period, with Ferring		12 months
Recognition period for exclusive license agreement payments		12 months
Pfizer License Agreement [Member]
Deferred Revenue Arrangement [Line Items]
Period for receiving royalties		3 years
ANI License Agreement [Member]
Deferred Revenue Arrangement [Line Items]
Term of the agreement									10 years

Segment_Information_and_Signif2

Segment Information and Significant Customers - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting Information [Line Items]
Number of operating segment	1
Outstanding accounts receivable	10.00%	10.00%
Sales Revenue, Net [Member]
Segment Reporting Information [Line Items]
Total revenue	10.00%	10.00%	10.00%

Segment_Information_and_Signif3

Segment Information and Significant Customers - Revenues By Customer Location (Detail) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting Information [Line Items]
Total revenues	$8,402,104	$6,570,581	$6,326,785	$5,202,195	$4,744,910	$5,507,824	$5,837,544	$4,528,222	$26,501,665	$20,618,500	$22,575,578
United States of America [Member]
Segment Reporting Information [Line Items]
Total revenues									21,409,371	16,479,855	16,964,635
Europe [Member]
Segment Reporting Information [Line Items]
Total revenues									4,761,684	3,901,422	4,936,981
Other [Member]
Segment Reporting Information [Line Items]
Total revenues									$330,610	$237,223	$673,962

Segment_Information_and_Signif4

Segment Information and Significant Customers - Revenues By Product Type (Detail) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting Information [Line Items]
Total revenues	$8,402,104	$6,570,581	$6,326,785	$5,202,195	$4,744,910	$5,507,824	$5,837,544	$4,528,222	$26,501,665	$20,618,500	$22,575,578
Injection Devices and Supplies [Member]
Segment Reporting Information [Line Items]
Total revenues									25,245,200	18,156,217	12,642,537
Transdermal Gel Products [Member]
Segment Reporting Information [Line Items]
Total revenues									$1,256,465	$2,462,283	$9,933,041

Segment_Information_and_Signif5

Segment Information and Significant Customers - Summary of Significant Customers Comprising 10% or More of Total Revenue (Detail) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting Information [Line Items]
Total revenues	$8,402,104	$6,570,581	$6,326,785	$5,202,195	$4,744,910	$5,507,824	$5,837,544	$4,528,222	$26,501,665	$20,618,500	$22,575,578
Teva [Member]
Segment Reporting Information [Line Items]
Total revenues									8,682,384	13,559,541	7,495,978
Ferring [Member]
Segment Reporting Information [Line Items]
Total revenues									4,760,084	3,827,098	4,933,369
McKesson [Member]
Segment Reporting Information [Line Items]
Total revenues									3,460,000
LEO Pharma [Member]
Segment Reporting Information [Line Items]
Total revenues									3,428,571	571,428
Actavis [Member]
Segment Reporting Information [Line Items]
Total revenues									$449,862	$1,489,942	$6,770,635

Segment_Information_and_Signif6

Segment Information and Significant Customers - Summary of Significant Customers Comprising 10% or More of Outstanding Accounts Receivable (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Teva [Member]
Segment Reporting Information [Line Items]
Outstanding accounts receivable	$1,455,284	$436,632
Ferring [Member]
Segment Reporting Information [Line Items]
Outstanding accounts receivable	651,897	562,576
McKesson [Member]
Segment Reporting Information [Line Items]
Outstanding accounts receivable	797,763
AmerisourceBergen [Member]
Segment Reporting Information [Line Items]
Outstanding accounts receivable	$448,483

Legal_Proceedings_Additional_I

Legal Proceedings - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014
	Patents
Commitments and Contingencies Disclosure [Abstract]
Legal costs capitalized as patent costs	$1,700,000
Number of patents	2

Quarterly_Financial_Data_unaud2

Quarterly Financial Data (unaudited) - Quarterly Financial Data (Detail) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Selected Quarterly Financial Information [Abstract]
Total revenues	$8,402,104	$6,570,581	$6,326,785	$5,202,195	$4,744,910	$5,507,824	$5,837,544	$4,528,222	$26,501,665	$20,618,500	$22,575,578
Gross profit	2,979,600	4,063,215	4,196,705	4,025,450	4,060,107	2,503,222	2,356,862	2,501,079	15,264,970	11,421,270	13,055,106
Net loss	($10,072,944)	($7,186,441)	($9,097,725)	($8,794,605)	($5,635,115)	($6,359,957)	($5,103,256)	($3,408,448)	($35,151,715)	($20,506,776)	($11,427,450)
Net loss per common share	($0.08)	($0.05)	($0.07)	($0.07)	($0.04)	($0.05)	($0.04)	($0.03)
Weighted average shares	131,694,429	130,771,380	130,051,896	129,656,257	127,835,641	127,162,064	126,462,677	126,106,713

Quarterly_Financial_Data_unaud3

Quarterly Financial Data (unaudited) - Quarterly Financial Data (Parenthetical) (Detail) (USD $)	3 Months Ended	12 Months Ended			3 Months Ended
	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014
Schedule Of Quarterly Financial Information [Line Items]
Research and development expense		$18,638,016	$15,263,371	$14,921,552
Licensing and royalty revenue in excess of licensing and royalty revenue in each of the prior three quarters	1,100,000
Otrexuptm [Member]
Schedule Of Quarterly Financial Information [Line Items]
Research and development expense	$243,000	$970,840	$243,000		$243,000	$243,000	$243,000